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ABSTRACT 
 
 
 
Role and Importance of NS1 Protein of Avian Influenza Virus to Grow in the Presence 
of Interferon and Evaluation of the NS1 Mutant Viruses as Potential DIVA Vaccines. 
(August 2009) 
Vinayak R. Brahmakshatriya, B.V.Sc. Maharashtra University, India; 
M.S., University of Delaware 
Co-Chairs of Committee: Dr. Sanjay Reddy 
  Dr. Blanca Lupiani 
 
 
 
 
A proper vaccination program can play a critical role in prevention and control of 
avian influenza (AI) in commercial poultry. Low pathogenic avian influenza viruses 
(LPAIV) of H5 and H7 AI subtypes cause serious economic losses to the poultry 
industry and have the potential to mutate to highly pathogenic AI (HPAI) strains. Due to 
trade implications, differentiation of infected from vaccinated animals (DIVA) is an 
important issue in the control of AI. Therefore, the development and characterization of 
vaccine candidates with DIVA properties is critical in improving vaccination programs. 
Keeping these aspects in mind, we investigated the role of an NS1 mutant virus as a 
potential live attenuated DIVA vaccine.  The NS1 protein of influenza virus plays a 
major role in blocking the host’s antiviral response.  Using an eight-plasmid reverse 
genetics system, we recovered the low pathogenic parental (H5N3) and NS1 mutant 
(H5N3/NS1/144) viruses. H5N3/NS1/144 expresses only the first 144 amino acids of the 
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NS1 protein compared to the 230 of the parental H5N3.  The growth properties of H5N3 
and H5N3/NS1/144 were compared in cell culture and in different age embryonated 
chicken eggs.  Our results confirmed that NS1 is involved in down regulation of 
interferon as shown by IFN-ß mRNA expression analysis and by the inability of 
H5N3/NS1-144 to efficiently grow in older age, interferon competent, chicken embryos.  
However with regards to safety the virus reverted to virulence within five back passages 
in chickens and was therefore not a safe vaccine candidate. However the killed form of 
H5N3/NS1-144 was a safer alternative and it also induced antibody titers and protection 
not significantly different from the parental H5N3 as vaccine. To further understand the 
reversion of H5N3/NS1/144 to virulence, we carried out 3 independent serial passages of 
H5N3/NS1/144 in increasing age of embryonated chicken eggs and examined the NS1 
gene for presence of mutations.  RT-PCR and sequence analysis of the NS gene in all 
three lineages showed the presence of a 54 amino acid deletion resulting in the 
generation of a 87 amino acids long NS1 ORF with a point mutation (L80V) at the site of 
deletion. In addition, the NS1 ORF in lineages L2 and L3 presented two additional point 
mutations in the RNA binding domain (Q40R and T73M).  To determine if these 
mutations played a role in increased virulence, recombinant viruses expressing these 
mutant NS1 proteins in the background of parental virus were generated by reverse 
genetics and their replication properties and pathogenicity was examined in vitro, in ovo 
and in vivo systems.  
Our results showed that the 87 amino acid long NS1 protein clearly increased 
virus replication and virulence specifically in interferon competent systems.  In addition, 
 v 
the two point mutations in the RNA binding domain of NS1 ORF expressing 87 a protein 
slightly increased the virus virulence. 
Overall this study reinforces the role of NS1 in influenza virus pathogenicity and 
supports the use of killed inactivated NS1 mutant virus vaccines as potential DIVA 
vaccines. 
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CHAPTER I 
 
INTRODUCTION AND REVIEW OF LITERATURE 
 
1.1 Classification of Influenza Viruses 
 Influenza viruses are members of the family Orthomyxoviridae and are important 
to both, veterinary as well as human health. The orthomyxoviridae family of viruses is 
divided into five different genera, including influenza virus A, B, C, Isavirus and 
Thogotovirus (Krug, 2001). Type A Influenza viruses can infect and cause disease in 
avian and mammalian species. Types B and C are limited to human infections, however 
in rare cases type C viruses have been isolated from other species (Shaw et al., 2008). 
Isaviruses infect fish species and include infectious salmon anemia virus (Kibenge et al., 
2004). Thogotovirus are tick borne viruses that can infect humans as well as animals 
(Kuno et al., 2001). 
 
1.2 Ecology and Pathobiology of Avian Influenza Viruses 
Avian influenza (AI) is a major respiratory disease of poultry caused by type A 
influenza viruses. AIV genome consists of eight linear negative-sense single stranded 
RNA segments, which code for eleven proteins, nine of which are structural and two are 
non-structural. The hemagglutinin (HA) and neuraminidase (NA) proteins are classified 
into 16 (HA) and 9 (NA) subtypes based on antigenic differences.  
_________________ 
This dissertation follows the style of Journal of General Virology. 
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Influenza virus genome being segmented, in situations of co-infection of a single 
cell with two influenza viruses belonging to different subtypes, viral gene segments can 
reassort. This can result in 144 possible HA and NA combinations. Wild aquatic birds 
(water fowl and sea gulls) are the natural host for AIVs and are considered reservoir for 
all possible subtypes of avian influenza viruses in nature (Halvorson et al., 1983).  In 
wild birds, AIVs usually replicate in the intestinal tract without causing disease, and 
spread by fecal contamination in water habitat. Often, AIVs infect non-natural hosts 
such as land-based poultry (chickens, turkeys and quail), pigs and humans without 
producing any clinical signs of infection.  However, occasionally, these AIVs can evolve 
to increased virulence causing significant morbidity and mortality.   
AIVs that infect poultry are further classified based on their pathogenicity as 
highly pathogenic (HP) and low pathogenic (LP) avian influenza. HPAIV include 
viruses, which may cause mortality as high as 100%. Until now, only viruses from the 
H5 and H7 subtypes have been classified as HPAIV although not all H5 and H7 viruses 
cause HPAI. The rest of the viruses cause LPAI (Thiermann, 2007) which can be 
manifested by mild respiratory disease, reduction in egg production and can be 
exacerbated by other pathogens and environmental conditions causing a much more 
serious disease. It is important to note that all LPAIV of the H5 and H7 subtypes are 
considered notifiable  (LPNAI) since they can mutate to HPAIV (Garcia et al., 1996; 
Hall, 2004; Rohm et al., 1995; Suarez et al., 2004).  
It is well documented that AI pathogenesis is a polygenic trait (Ito et al., 2001; 
Rott et al., 1979; Stephenson et al., 2004). In this regard, it has been shown that the 
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cleavability of the HA protein plays an important role since it restricts tissue tropism. 
HA is synthesized as a precursor (HA0), which must be cleaved, post-translationally, by 
host proteases to create functional HA protein and produce infectious virus particles. 
While HA0 of HPAIVs are cleaved by ubiquitous furine-like proteases(Rott et al., 1995), 
HA0 of LPAIVs are cleaved by trypsin-like proteases present only in the respiratory and 
enteric tracts (Klenk & Rott, 1988). As a consequence, infection with HPAIV cause 
systemic infections that result in numerous vital organs being affected while LPAIV 
cause localized respiratory or intestinal infections. 
 
1.3 Morphology and Composition  
Morphologically influenza viruses vary from spherical to filamentous shapes 
with a diameter of 80-120 nm and up to several microns in length. Influenza viruses are 
composed of viral structural proteins and a lipid membrane from host origin (Krug, 
2001). Type A influenza virus genome consists of eight negative single-stranded RNA 
segments, which code for 11 proteins. The three largest segments encode for the three 
viral polymerase subunits, PB1, PB2, and PA, and an alternate reading frame in PB1 
encodes the non-structural pro-apoptotic protein PB1-F2. Two medium sized segments 
code for the structural glycoproteins; hemagglutinin (HA) and neuraminidase (NA), 
which form projections on the surface of the virus particle and are important antigenic 
determinants. The viral nucleoprotein together with the viral RNA and the polymerase 
complex forms 8 ribonuceloproteins (RNP). RNP has a helical structure and consists of 
the viral RNA wrapped around the nucleocapsid protein (NP), encoded by the medium 
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sized viral gene segment. NP makes the viral RNA accessible to the replication 
machinery. The two smallest segments encode two proteins each. The NS segment 
encodes the non-structural protein 1 (NS1) and nuclear export protein (NEP). The M 
segment encodes for the matrix protein (M1), which covers the inside of the viral 
envelope, and the membrane bound ion channel-like protein (M2). The lack of 
proofreading mechanisms of the viral RNA polymerase complex makes the viral genome 
highly variable, with viable mutations occurring in the HA and NA genes resulting in 
several different subtypes.  
 
1.4 Replication of Avian Influenza Viruses 
           Hemagglutinins present on the surface of AIV binds to sialic acid sugars on target 
cells. Virus then enters the cells via receptor-mediated endocytosis and, upon 
acidification of the endocytic vesicle the viral membrane fuses with membrane of the 
vesicle releasing the viral nucleocapsid into the cytoplasm (Krug, 2001). The viral 
nucleocapsid is then transported to the nucleus where the negative stranded viral RNA is 
transcribed by the viral polymerase complex into mRNA, using capped 5’ ends of host 
pre mRNAs as primers to initiate synthesis (Plotch et al., 1981). These viral mRNAs are 
then transported to cytoplasm where they are translated into viral proteins.  A small 
number of NS and M viral segments mRNAs are spliced in the nucleus prior to being 
transported to the cytoplasm. mRNAs specifying for viral membrane proteins (HA, NA, 
M2) are translated in the rough endoplasmic reticulum where they enter the secretory 
pathway in which they undergo glycosylation (Krug, 2001). Protein of the polymerase 
 5 
complex (PA, PB1, PB2) and NP are imported into the nucleus where they catalyze 
synthesis of full-length positive strand RNA (cRNA) followed by negative sense virion 
RNA. M1 and NS1 viral proteins are also transported into the nucleus, where M1 shuts 
down viral mRNA synthesis and in conjunction with NS2 aids in the export of RNPs to 
the cytoplasm (Krug, 2001). HA, NA and M2 proteins are transported to the cell surface 
and become incorporated in the plasma membrane while M1 migrates to the inner part of 
the cell membrane making contact with the cytoplasmic tails of HA and NA and the 
RNPs, linking the inner core components and the membrane proteins. Assembly of the 
virion is then completed at this location by budding from the plasma membrane.  
 
1.5 Immune Protection in Avian Influenza Virus Infection 
 The goal of AI vaccination is to induce an immune response that not only protects 
against disease but also prevents infection and shedding. The “gold standard” for 
assessing protective immunity is the use of LPAI or HPAI virus challenge models 
(Swayne & Kapczynski, 2008b). The criteria for protection for HPAIV challenge is in 
terms of morbidity and mortality (Brugh et al., 1979; Stone, 1987; 1988; Wood et al., 
1985). On the other hand, experimental LPAIV challenges typically do not produce 
clinical signs or death and as a result, such criteria cannot be used in assessing vaccine 
protection against LPAIV. Instead, quantitative virus reduction in respiratory/digestive 
tract is the main criteria to evaluate protection (Capua et al., 2004; Swayne, 2003; 
Swayne et al., 1997).  
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1.5.1 Innate Immune Response and Avian Influenza 
Innate immunity is non-specific, depends on factors that exist prior to microbe 
invasion and is capable of a rapid response to pathogens. The innate immune system 
detects pathogens through pattern recognition receptors (PRRs) (Koyama et al., 2007) 
which recognize molecular markers of microbes known as pathogen associated 
molecular patterns (PAMPs). To detect and immidiately induce an innate immune 
response, different host species use a variety of sensors which follow in two main 
classes:   
a. Toll like receptors (TLRs): TLRs are transmembrane proteins containing 
luminal leucine-rich repeats (LRRs) that sense pathogen-associated molecular patterns 
(Kawai & Akira, 2007). TLRs, involved in the detection of viral nucleic acids are 
located on the cell surface (TLR3) or in endosomal compartments (TLR3, TLR7, TLR8, 
and TLR9) (Iwasaki & Medzhitov, 2004).  TLRs involved in detection of influenza 
viruses are TLR3 and TLR7/8.  
b. Retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs): RLR family 
member, RIG-I, is a cytoplasmic protein that detects single stranded viral RNA products; 
therefore, it can detect influenza viruses within the cytosol (Kato et al., 2006).  
Influenza virus infection induces TLR and RIG-I pathways leading to the 
activation of inflammatory cytokine production, mainly interferon (IFN) α/β 
(McCartney & Colonna, 2009). 
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 Interferon produced upon stimulation of the innate immune response, binds to 
homologous receptor complex IFNAR and induces transcription of more than 100 IFN-
stimulated genes (ISGs), whose combined action leads to the generation of an "antiviral 
state" in non-infected cells (Bluyssen et al., 1996; Haque & Williams, 1994; Stark et al., 
1998). The antiviral molecules stimulated by IFN are: protein kinase stimulated by 
dsRNA (PKR), 2'-5' oligoadenylate synthetases (OAS) and myxovirus resistance gene 
(Mx) (Biron et al., 2001). While Mx sequesters viral ribonucleoproteins to specific sub-
cellular compartments, PKR phosphorylates downstream substrates upon recognition of 
dsRNA, including the elongation initiation factor eIF2-α, resulting in the inhibition of 
protein translation. The OAS proteins are also activated by dsRNA, leading to the 
generation of 2'-5' oligoadenylates, which activate ribonuclease L (Rnase L) that 
degrades cellular and viral RNA. Both PKR and the OAS/RNaseL systems have 
profound inhibitory effects on basal cellular processes that eliminate virus-infected cells 
by suicide (Samuel, 2001). IFN can also induce antiviral effect through other multiple 
pathways (Zhou et al., 1999) suggesting that hosts have evolved redundant pathways to 
resist virus infection by using multiple mechanisms to counteract viral resistance to one 
particular pathway; also different factors of the IFN system mediate inhibition of 
specific virus families (Garcia-Sastre & Biron, 2006). 
1.5.2 Adaptive Immune Response and Avian Influenza 
Cytokines secreted during the induction of innate immune response stimulate and 
influence the nature of the adaptive immune response. A CD4+ T-helper type 1 response 
profile includes gamma interferon, IL-2, 15, 18 and is associated with a strong CD8+ T- 
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cell-specific response (Swayne & Kapczynski, 2008b). Previous studies have shown that 
CD8+ CTL directed against viral HA and NP epitopes conserved among influenza A 
viruses contribute to protection (Altstein et al., 2006; Anderson et al., 1992).  CD4+ T 
helper type-2 response profile includes IL-4, 5,10 and stimulate antibody production 
(Swayne & Kapczynski, 2008b). In poultry, during natural infection, the humoral 
immune response includes systemic as well as mucosal antibody production. The 
humoral immune response plays a principal role in protection against AIV (Chambers et 
al., 1988). Antibodies against HA block viral attachment to host cells, preventing 
infection. As a result, the immune protection offered, is strongest against the specific or 
closely related strains, depending on antigenic relatedness.  On the other hand, 
antibodies to NA provide only partial protection against HPAIV challenge (Sylte et al., 
2007). Similarly, internal proteins have been shown to provide insufficient protection, 
although they induce a good antibody response (Brown et al., 1992; Webster et al., 
1991). The strong antibody response to NP has, however important diagnostic 
applications as it allows the monitoring of flocks by screening for antibodies to this 
highly immunogenic protein. Secretory antibodies probably play an important role in the 
recovery of infected birds and by provides protection from further infections, 
particularly in the case of LPAI, which is primarily a mucosal infection. Mucosal 
infection by viruses like AIV also results in the induction of cell-mediated immunity, as 
manifested by CD4+ T helper-type 1 cells, as well as CD8+ cytotoxic T-lymphocytes. 
These responses result in synthesis of secretory immunoglobulin A (S-IgA) antibodies, 
which provide an important first line of defense against invasion of deeper tissues by 
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these pathogens (van Ginkel et al., 2000)(ref). Resistance of S-IgA to proteolysis in 
external secretions and greater ability to prevent attachment of influenza virus as 
compared to IgY and monomeric IgA (Taylor & Dimmock, 1985) emphasizes the role 
and importance of mucosal immunity in controlling avian influenza.  
 
1.6 The Influenza A Virus NS1 (NS1A) Protein 
The NS gene of influenza A virus encodes two different proteins, NS1 and 
nuclear export protein (NEP) (Esposito et al., 2006). NS1 of influenza A viruses 
contains around 230/237 amino acid residues depending on strain of the virus. NEP is a 
product of the spliced NS mRNA and shares the first 10 amino acids with NS1. NS1 is 
the most abundant nonstructural protein of influenza A virus expressed in infected cells. 
The NS1 protein of influenza viruses has been shown to block the cellular interferon 
pathway, which plays a crucial role in the innate antiviral defense mechanism of 
eukaryotic cells. (Bergmann et al., 2000; Garcia-Sastre et al., 1998; Hale et al., 2008b; 
Kochs et al., 2007). The amino-terminal domain of the NS1 protein of influenza A virus 
has a double stranded (ds) RNA binding domain, which inhibits the synthesis of IFN α/β 
by preventing the activation of double-stranded RNA mediated activation of protein 
kinase R (Bergmann et al., 2000). The carboxy-terminal domain of NS1 contributes to 
its IFN-antagonistic properties, possibly by enhancing NS1 stability (Wang et al., 2002) 
and by binding cellular proteins involved in mRNA synthesis. There has been increasing 
interest in using NS1 mutant viruses as a “modified live vaccine” since it is attenuated in 
growth in immunocompetent host and could also induce rapid release of several 
 10 
inflammatory cytokines. However, replication of influenza virus lacking the entire NS1 
coding region, is severely inhibited resulting in weak induction of protection. Therefore, 
influenza viruses expressing truncated NS1 proteins could have reduced virulence 
causing attenuation of the virus without compromising immune protection against a 
challenge. 
1.6.1 Structure and Function of NS1 
NS1 protein was first identified more than 35 years ago. However only in the last 
decade, the function of NS1 during influenza A virus infection has begun to be 
understood. NS1 protein is multi-functional with a major function being in post-
transcriptional regulation of cellular gene expression (Hale et al., 2008a). 
 
 
 
 
 
 
Fig.1. Schematic representation of the functional domains of the NS1 protein of type A 
influenza virus. The location of binding domains of known cellular proteins are 
indicated. 
 
 
1.6.1.1 Structure and Function of the N-terminus 
The RNA-binding domain (RBD) of NS1 is located at its N-terminal end. An N-
terminal structural domain, which comprises the first 73 amino acids of the intact protein 
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NS1 (1-73), possesses all of the dsRNA binding activities of the full-length protein 
(Bornholdt & Prasad, 2008) as shown in Fig 1.  
The NS1 RBD is almost totally α-helical and forms a symmetrical homodimer 
with a unique six-helical chain fold. Each polypeptide chain of the RBD consists of three 
α-helices (Bornholdt & Prasad, 2008): α -helix 1: Asn4-Asp24; α -helix 2: Pro31-Leu50 
and α -helix 3: Ile54- Lys70 X-ray crystal structure of NS1 RBD has shown that it forms 
a symmetric homodimer in solution. Interestingly, the RBD of NS1 does not share any 
sequence homology with any known RNA binding protein (Liu et al., 1997). NS1 with a 
unique six-helical chain fold. Each polypeptide chain of the RBD consists of three α-
helices (Bornholdt & Prasad, 2008): α -helix 1: Asn4-Asp24; α -helix 2: Pro31-Leu50 
and α -helix 3: Ile54- Lys70 X-ray crystal structure of NS1 RBD has shown that it forms 
a symmetric homodimer in solution. Interestingly, the RBD of NS1 does not share any 
sequence homology with any known RNA binding protein (Liu et al., 1997). NS1 
possesses a positive electrostatic charge due to a high content in basic amino acid 
residues (Chien et al., 1997), which play an important role in binding sites to both 
double-stranded and single-stranded nucleic acids.  
1.6.1.2 Structure and Function of C Terminus 
The C-terminus of the NS1A protein mainly contains binding domains to three 
cellular proteins: eIF4GI, 30 kDa subunit of CPSF (CPSF30) and PAB II. 
Like the RBD, the effector domain also forms dimers (Bornholdt & Prasad, 2006). Each 
monomer consists of seven β strands and three α-helices. NS1 binds two CPSF subunits 
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per dimmer which result in the efficient shut down of cellular mRNA maturation and 
export.  
The NS1 effector domain inhibits host mRNA maturation by interfering with 
mRNA polyadenylation (Nemeroff et al., 1998), mRNA nuclear export (Fortes et al., 
1994) and pre-mRNA splicing (Fortes et al., 1994; Lu et al., 1994; Qiu et al., 1995). The 
effector domain of NS1 also enhances viral replication by interacting with the eukaryotic 
translation initiation factor 4GI (eIF4GI), resulting in a preferential translation of viral 
mRNAs over host mRNAs (Burgui et al., 2003) and modulates viral RNA transcription 
and replication (Shimizu et al., 1994). NS1 has also been shown to interact with the 
retinoic acid-inducible gene I product (RIG-I) inhibiting downstream activation of IRF-3 
and therefore preventing transcriptional induction of IFN-β (Mibayashi et al., 2007). 
Recently, the residue at position 92 of H5N1 virus was shown to be crucial for virulence 
of the virus (Seo et al., 2002). Most viruses present a Asp at position 92, and its mutation 
to Glu is linked to increased virulence and cytokine resistance in certain H5N1 strains 
(Seo et al., 2002). Asp interacts with Ser195 and Thr197 of NS1 protein, which is 
phosphorylated by the nucleocapsid protein and destabilizes NS1, leading to the 
induction of apoptosis. The mutation Asp92Glu lowers the efficiency of NS1 
phosphorylation, resulting in a virulent phenotype by prolonging the viral life cycle 
(Bornholdt & Prasad, 2006). 
  Recently, residues 80–84 in H5N1 strains have been implicated in cytokine 
resistance but not virulence (Long et al., 2008). These residues are part of a flexible 
linker between the RBD and the effector domain, and thus their deletion may greatly 
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alter the orientation or stability of the RBD, or both. This deletion could compact NS1 
and confer more stability to the RBD, possibly by increasing dsRNA-binding affinity (Li 
et al., 2004). 
Despite the importance of the above-mentioned functions of NS1, it has been 
shown that NS1 is not absolutely required for virus replication.  Influenza viruses 
lacking NS1 or containing truncated forms of the gene are able to replicate well in hosts 
which are defective in IFN production (Vero cells, STAT-/- mice and 7-day-old 
embryonated eggs) (Egorov et al., 1998; Garcia-Sastre et al., 1998; Quinlivan et al., 
2005), while their replication in IFN competent hosts is significantly reduced (MDCK 
cells, normal mice, 10-day-old embryonated chicken eggs and pigs) (Egorov et al., 1998; 
Garcia-Sastre et al., 1998; Quinlivan et al., 2005; Solorzano et al., 2005).  
Although the work cited above provides convincing evidence that NS1 is a major 
IFN antagonist, the mechanisms by which this process takes place continue to emerge. 
Further to this point, most experiments directed to identify the role of NS1 in 
counteracting the host IFN response have been conducted with human attenuated or 
avian viruses infecting humans in vitro, in mammalian animal models (Garcia-Sastre et 
al., 1998; Talon et al., 2000), and only more recently, with swine (Solorzano et al., 
2005) and chicken viruses (Cauthen et al., 2007) in their natural host. In addition, 
because the functional properties of wild type and mutant viral proteins could be very 
different in their natural host, it is important to undertake a molecular and pathogenesis 
integrated approach to study the mechanisms of NS1 induced pathogenesis in chickens. 
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1.7 Prophylaxis for Avian Influenza Virus Infection 
Avian influenza prevention strategies in commercial poultry are designed to 
achieve the following three goals (Swayne & Kapczynski, 2008a): (a) Prevention of 
infection; (b) Management and preventing the spread of an ongoing outbreak, to 
minimize economic losses; and (c) Eradication. 
         Strategies employed to achieve the above objectives include (Swayne & Kapczynski, 
2008a): 
1. Biosecurity measures: Quarantine and movement restrictions at regional, national 
and international levels, to prevent the spread of AI. 
2. Surveillance and diagnostic programs: Aimed at early detection of potential 
pathogenic AIVs and to be informed on circulating AIV strains in nature. 
3. Elimination of infected chickens: Policy of stamping out of infected chickens or 
controlled marketing of recovered or vaccinated chickens. 
4. Decrease host susceptibility and increased resistance to AI: Through vaccinations 
and improvement in host genetics.  
Criteria for vaccine licensing by the Animal and Plant Health Inspection Service 
(APHIS) of the USDA (Myers et al., 2003): 
a. Purity: The vaccine contents should exclusively contain the desired 
compounds and should be consistent in production.  
b. Safety : Vaccine should not cause any harmful effects on the host or 
environment. 
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c. Efficacy: Quantified standards of protection including decreased 
mortality, decreased virus shedding against homologous and heterologous 
challenge.  
d. Potency: Maximum protection in least possible dosages. 
 
1.8 Current and Experimental Poultry AI Vaccines  
The currently licensed vaccines used in the United States are inactivated whole 
AIV vaccines and a recombinant fowlpox virus (rFP-AIV-H5) vaccine, which expresses 
the HA from A/turkey/Ireland/83/H5N8 (Swayne, 2006). A variety of HA subtype 
vaccines have been licensed under autogenous, conditional and full licensure categories 
as inactivated AI vaccines. In the US, field application of any H5 and H7 vaccines 
requires the approval of the state and federal government, but other subtypes require 
only state government approval. The licensing procedures in other countries of AI 
vaccines depends on the specific requirements of national veterinary biologics authority 
of that particular country in areas of safety, purity, potency and label approval for 
species, age and route of administration (Swayne & Kapczynski, 2008b). Globally, the 
majority of licensed vaccines are inactivated whole AI virus vaccines, principally of H5, 
H7, and H9 subtypes. In the current H5N1 HPAI epidemic, LPAIV seed strains from 
previous outbreaks have been used with the exception of A/chicken/Legok-
Indonesia/03/H5N1, which is the only HPAIV used as a killed vaccine seed 
strain(Swayne & Kapczynski, 2008b). In recent years reverse genetic derived infectious 
clone seed strains have been developed using 6 internal genes from PR8 influenza A 
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vaccine strain and HA and NA from various HPAIV strains. In Asia, fowl pox-vectored 
and Newcastle disease virus- vectored vaccines incorporating HA gene, where HA gene 
was altered from HPAIV to an LPAIV.(Ge et al., 2007).  
1.8.1 Inactivated AI Virus Vaccines 
Preparation of Inactivated vaccines for avian influenza for chickens require three 
important steps: 
a. Propagation of avian influenza virus in embryonated chicken eggs 
b. Chemical inactivation of the virus using formalin, beta-propiolactone or binary 
ethyleneimine. 
c. Preparation of oil-emulsion of the inactivated virus 
Preparation and administration cost for killed vaccine on a commercial scale are 
much higher than that for live vaccines. However, killed vaccines are much safer than 
live attenuated vaccines, especially in case of influenza, since AIVs have the potential to 
mutate and recombine raising the risk of the vaccine virus to regain virulence. To reduce 
costs, poultry AI vaccines are not purfied and therefore structural (HA, NA, NP, M1, 
M2) and non-structural (NS1) proteins are present in the vaccine preparation (Suarez, 
2005). Inactivated vaccines induce a strong antibody response but a weaker cell 
mediated immune response (Subbarao et al., 2006). In recent years, in addition to the oil 
phase, different adjuvants have been added to inactivated vaccine formulations to 
increase immunogenicity (Fatunmbi et al., 1992; Stephenson et al., 2005). Such 
adjuvants include innate immune response stimulators such as toll like receptor ligands, 
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microbial components, or cytokines that independently induce a cell mediated immune 
response (Vogel, 2000). 
1.8.2 AI Protein Subunit Vaccines 
Studies have been conducted, where chickens are vaccinated with only one 
particular recombinant protein instead of including the entire virus. In case of AI since 
HA is the major neutralizing antigen, HA proteins from different strains of AI have been 
expressed in different systems such as animal or plant cells, bacteria, viruses and yeast 
(Chambers et al., 1988; Crawford et al., 1999; Davis et al., 1983; De et al., 1988; 
Saelens et al., 1999; Schultz-Cherry et al., 2000). The HA protein is then purified, 
quantified, oil emulsified, and parenterally injected. These vaccines are very safe, 
because no live AI virus is involved, however vaccine production costs may be too high 
to replace the traditional efficacious inactivated AI vaccines. Baculovirus vectors have 
also been used to express the HA of both H5 and H7 subtypes in culture supernatants of 
insect cells, which when used to immunize poultry have provided protection from H5 
and H7 HPAI challenge (Crawford et al., 1999). 
1.8.3 Vectored Vaccines Expressing AI Genes 
Several viral vectors such as infectious laryngotracheitis virus, vaccinia virus, 
human adenovirus 5, Venezuelan equine encephalitis virus, and retrovirus have been 
studied for expression of AIV proteins (Brown et al., 1992; Chambers et al., 1988; De et 
al., 1988; Gao et al., 2006; Hunt et al., 1988; Luschow et al., 2001; Toro et al., 2007; 
Veits et al., 2006). However, the most well known example in poultry is the recombinant 
fowl pox (rFP) vector containing the HA gene from either H5 or H7 subtype AIV (Beard 
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et al., 1992; Boyle et al., 2000; Bublot et al., 2007; Bublot et al., 2006; Jia et al., 2003; 
Qiao et al., 2003; Swayne et al., 2000; Webster et al., 1991). rFP vaccines expressing 
H5 HA have been commercialized and used extensively in Mexico, El Salvador and 
Guatemala with over 2 billion doses used from 1997 to 2006, and a rFP expressing both 
H5 and N1 genes has been used in China (Swayne, 2008; Swayne et al., 1997; Villarreal, 
2006). Though these vaccines need to be administered parenterally, they can be applied 
early on in the hatchery (1 day of age), compared to 1-2 weeks of age in case of a killed 
vaccine, thus saving the labor of handling chickens. 
1.8.4 DNA Vaccines 
Plasmid DNA-based vaccines expressing the AI HA gene, under control of a 
eukaryotic promoter, have been shown to elicit protective immunity in chickens 
following H5 and H7 HPAI challenge (Fynan et al., 1993; Jiang et al., 2007; Kodihalli et 
al., 1997; Le Gall-Recule et al., 2007; Robinson et al., 1993; Suarez & Schultz-Cherry, 
2000b). In poultry, DNA vaccines can be administered by intramuscular, subcutaneous 
and in ovo routes of inoculation. DNA vaccination results in protein expression eliciting 
both cytotoxic and humoral mediated immunity and closely mimics live virus vaccines. 
However, current limitations for DNA vaccines include the high cost for manufacturing 
and the requirement of multiple vaccinations to achieve protective immunity. 
1.8.5 Live Virus AI Vaccines 
Live LPAI virus vaccines can provide protection against HPAI virus challenge 
and may be mass applied to commercial poultry. Since live virus vaccines induce 
humoral, cellular, and mucosal immunity, they provide superior protection compared to 
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inactivated vaccines (Beard & Easterday, 1973). However, the potential for live viruses 
to mutate and reassortant, especially for H5 and H7 subtypes, which have been shown to 
mutate from LPAI to HPAI viruses, precludes their use to control AI by the poultry 
industry. In recent years there has been increased interest in using truncated NS1 mutant 
viruses as a live attenuated vaccine since the NS1 gene impacts virulence and evasion of 
the host immune response, making them ideal candidates for live AI virus vaccines 
(Quinlivan et al., 2005; Solorzano et al., 2005). 
 
1.9 Evaluation of Vaccine Efficacy  
1.9.1 Direct Evaluation 
The assessment of poultry AI vaccines for their ability to protect against LPAIV and 
HPAIV is best accomplished using a challenge model using a current circulating virus 
strain as a challenge virus. The following measures of protection can be used: 
a. Prevention of clinical signs and death (Stone, 1987). 
b.  Prevention of egg production drops (Brugh et al., 1979; Stone, 1987). 
c. Quantitative reduction in challenge virus shed from respiratory and 
gastrointestinal tracts (Swayne et al., 1997). This can be achieved by virus 
isolation in embryonating chicken eggs or tissue culture systems. Alternatively, 
quantitative realtime PCR has been used in recent years (Wang et al., 2008) to 
quantitate virus shedding. 
d. Prevention of contact transmission is a desirable goal. Contact transmission 
studies have been carried out by introducing uninfected chickens as contact-
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control chickens into cages with infected chickens one day after infection (Wang 
et al., 2008). However the assessment is difficult due to multiple variables such 
as bird density, sanitation and ventilation standards, which have to be taken into 
consideration during transmission in field situation.  
e. Additional Attributes: Besides reducing virus shed and preventing clinical signs 
other important attributes include: (1) protection against high dose challenge (2) 
early and long periods of protection spanning 6-12 months (Swayne et al., 1997).  
(3) Minimum number of vaccinations to achieve protection. (4) Protection in 
multiple species of birds 
1.9.2 Indirect Evaluation 
Direct evaluation of vaccine is important for initial demonstration of vaccine 
efficacy. However once the efficacy of the vaccine is established, parameters such as 
serological response can be used to monitor vaccine efficacy of the vaccine in field 
condition (Swayne, 2008). Serological assays such as neutralization or hemagglutination 
inhibition titers are good and reliable tests for monitoring vaccine efficacy (Swayne, 
2008). Decreased immune response could be caused due to vaccine failure or due to 
changes in circulating viruses.  
 
1.10 Drawbacks of Current Avian Influenza Vaccines 
A major disadvantage of vaccination against avian influenza, using traditional 
vaccines is the need to vaccinate against different HA and NA subtypes since the 
heterosubtypic imunne response is not protective (Suarez & Schultz-Cherry, 2000a) and 
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the circulating  virus subtypes keep changing. Therefore, the current influenza research 
focus has been to develop a vaccine that will be protective for all influenza type A 
viruses. There are several highly conserved influenza proteins such as NP, M1 and M2 
which are potential candidates for providing broad cross protection against 
heterosubtypic influenza viruses (Suarez & Schultz-Cherry, 2000a). However, vaccines 
eliciting primarily neutralizing antibody response are effective, the antibodies against NP 
and M1 internal proteins are not useful, since antibody to these proteins are not 
neutralizing and therefore not protective. The M2 protein, an influenza surface protein, 
provides a broad but limited protection in mice, and it has not yet been tested in poultry 
(Frace et al., 1999; Zebedee & Lamb, 1988). Induction of cell-mediated immune 
response has been considered to play an important role in protection against virus 
infections (Suarez & Schultz-Cherry, 2000a). Some research has been conducted to 
stimulate a cell-mediated immune response to the NP, since it is a well-conserved 
influenza A viral protein. The use of DNA vaccines containing the NP gene has shown 
limited protection against a heterotypic challenge in mice and ferrets (Bot et al., 1996; 
Donnelly et al., 1997; Ulmer et al., 1994; Ulmer et al., 1993). Moreover, fowlpox and 
retrovirus vectored vaccines expressing the NP gene were unable to generate a protective 
response in poultry. This is surprising since the use of live virus should have stimulated 
a cellular immune response (Brown et al., 1992; Webster et al., 1991). Another issue 
with cell mediated immunity is that a detectable response is not seen, until 4 days after 
challenge (Kodihalli et al., 1994). This delayed cell mediated immune response, appears 
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unlikely to protect from HPAI that can cause death as early as 1 day after experimental 
challenge (Suarez et al., 1998).  
In summary the current vaccines, inducing antibody response to neutralizing 
epitopes of avian influenza confer an effective protection against homologous but not 
heterologous challenge. On the other hand, induction of cell-mediated immune response 
to conserved structural epitopes is believed to confer protection against different 
subtypes. However with current understanding such vaccines have been able to 
demonstrate only limited protection.against avian influenza challenge.  
 
1.11 Potential of NS1 Mutant Virus as DIVA Vaccine 
Due to trade implications, vaccination of chickens is not routinely practiced 
because of the inability to serologically differentiate infected from vaccinated animals 
(DIVA). Earlier studies have shown that it is possible to differentiate vaccinated from 
infected chickens based on NS1 protein  (Zhao et al., 2005). Using runcated NS1 mutant 
viruses as vaccines the vaccinated chickens can be differentiated from infected chickens 
based on lack of antibodies against complete NS1 protein. The absence of antibodies 
against NS1 could be used to differentiate between vaccinated and infected chickens 
(Lee et al., 2004; Suarez, 2005).  However, commercial poultry vaccine manufacturing 
incorporates some non-structural proteins (Suarez, 2005) as these vaccines are not 
purified, which can in turn interfere in serosurvielence of AIV. In such circumstances an 
NS1 mutant virus could be used as a vaccine seed stock, which would enable 
differentiation between vaccinated and infected chickens. Because the NS1 gene impacts 
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virulence and evasion of the host immune response, this virus exhibited decreased 
replication and attenuation of infectivity, desirable traits for a live AI virus vaccine, thus 
providing an example for attenuated live virus vaccines. 
Recently, an AI virus with natural truncation in NS1 ORF was passaged for 
several rounds in 14-day-old ECE causing further truncations in the NS1 gene. This 
virus was shown to be attenuated in chickens and was shown to induce protection 
against a subsequent virulent challenge (Steel et al., 2009; Wang et al., 2008). On 
similar lines in a different study besides truncations in NS1 ORF point mutation was 
introduced in PB2, changing K at position 627 to E. This change was shown to cause 
further attenuation. These viruses were shown to be attenuated and protective, however 
their safety in terms of reversion to virulence was not tested in chickens. 
 
 
 
 
 
 
 
 
 
 24 
CHAPTER II 
 
 
CHARACTERIZATION AND EVALUATION OF AVIAN INFLUENZA NS1 
MUTANT VIRUS AS A POTENTIAL LIVE AND KILLED DIVA 
(DIFFERENTIATING BETWEEN INFECTED AND VACCINATED ANIMALS) 
VACCINE FOR CHICKENS 
 
2.1 Introduction 
Avian influenza is a major respiratory disease of poultry caused by type A 
influenza viruses.  Type A influenza viruses are members of the Orthomyxoviridae 
family and their genome consists of 8 RNA segments of negative polarity. The 8 
segments code for a total of 11 proteins: 3 polymerase components (PA, PB1 and PB2), 
3 membrane proteins (hemagglutinin or HA, neuraminidase or NA and ion channel 
protein or M2), a matrix protein (M1), a nucleocapsid protein (NP), a nuclear export 
protein (NEP) and two non-structural proteins (NS1 and PB1-F2). 
Type A influenza viruses are also classified into subtypes based on the antigenic 
reactivity of the HA (16 subtypes) and NA (9 subtypes) proteins present on the viral 
envelope (Fouchier et al., 2005; Webster et al., 1992). Wild aquatic birds (water fowl 
and sea gulls) are the natural reservoirs for all subtypes of type A influenza viruses 
(Fouchier et al., 2005; Webster et al., 1992). On occasions, these viruses can infect non-
natural hosts such as land-based poultry (chickens, turkeys and quail) without producing 
any clinical signs of infection.  However, sporadically, these influenza viruses can 
evolve to increased virulence causing extensive economic losses (Alexander, 2000; 
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2007; Garcia et al., 1996; Rohm et al., 1995). Avian influenza viruses (AIV) are also 
classified as highly pathogenic (HP) or low pathogenic (LP) based on their virulence.  
HPAIV produce systemic infections and mortality may be as high as 100%.  On the 
other hand, LPAIV cause a mild, primarily respiratory disease in poultry, which may be 
exacerbated by other infections or environmental conditions. HPAI originates from 
LPAI viruses, which are present in many wild bird species throughout the world. Thus 
all countries are potentially at risk of being infected with HPAI, this phenomenon has 
been well demonstrated in recent years with the global spread of H5N1 (Swayne & 
Kapczynski, 2008a).    
Pathogenesis of AIV is a polygenic trait and HA, PB1, PB2, PA, N and NS1 have 
been implicated in host range and pathogenicity of influenza viruses (Asplin, 
1970Cheung, 2002 #5356; Easterday et al., 1968; Hatta et al., 2001; Hinshaw et al., 
1986; Li et al., 2005; Lipkind et al., 1981; Perkins & Swayne, 2002; 2003; Seo et al., 
2002; Shinya et al., 2004) The non-structural protein, NS1 is considered a virulence 
factor due to its ability to block the cellular interferon pathway (Garcia-Sastre, 2001; 
Wang et al., 2000). The amino-terminal end of NS1 has a double stranded (ds) RNA 
binding domain, which inhibits the synthesis of IFN α/β by preventing the activation of 
double-stranded RNA mediated activation of protein kinase R (Wang et al., 2000). The 
carboxy-terminal end of NS1 contributes to its IFN-antagonistic properties, possibly by 
enhancing NS1 stability (Nemeroff et al., 1995; Wang et al., 2002) and by binding 
cellular proteins involved in mRNA synthesis. There has been increased interest in the 
use of NS1 mutant influenza viruses as “modified live vaccines” because of their 
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attenuated growth in immunocompetent hosts and also their induction of several 
inflammatory cytokines such as IL1β and IL6 (Ferko et al., 2004).  Besides inhibiting 
the innate immune response, NS1 can also affect the adaptive immune response by 
inhibiting dendritic cell maturation and their capacity to induce T cell responses 
(Fernandez-Sesma et al., 2006). However, replication of influenza virus lacking the 
entire NS1 coding region, is inhibited to a great extent resulting in weak induction of 
immune response. Therefore, attenuated truncated NS1 mutant viruses are potential 
candidates for live attenuated vaccines.  
Due to trade implications, vaccination of chickens is not routinely practiced 
because of the inability to serologically differentiate infected from vaccinated animals 
(DIVA) (Suarez, 2005). Different approaches have been sought, for developing AIV 
vaccines with DIVA properties.  It has also been shown that it is possible to differentiate 
vaccinated from infected chickens based on antibodies to NS1 protein using killed 
vaccine (Zhao et al., 2005). NS1 being a non-structural protein, is absent when purified 
virions are used as a killed vaccine. However, poultry vaccine manufacturing on a 
commercial scale includes non-structural proteins (Suarez, 2005) and in such a situation 
an NS1 mutant AIV in which the more immunogenic domain (carboxy end) (Birch-
Machin et al., 1997) has been deleted could be used as a seed virus for making vaccines 
and DIVA strategy could be feasible option. A similar DIVA approach was 
demonstrated for swine influenza viruses, where the vaccinated animals could be 
serologically differentiated based on the presence or absence of antibodies to NS1 while 
still inducing protection against challenge (Richt et al., 2006).  
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A DIVA approach would have a great impact for the poultry industry where AIV 
vaccines are used. In this study we assessed the biological properties and potential use 
and safety of an NS1 mutant virus with DIVA potential as live attenuated as well as 
killed vaccine.  
 
2.2 Materials and Methods 
2.2.1 Cells and Viruses 
DF1, a chicken embryo fibroblast cell line, was cultured in Leibovitz and 
McCoy’s growth medium containing 5% fetal bovine serum (FBS). Chicken embryo 
fibroblasts (CEF), aged chicken embryo cells (A-CEC) and 293-T human embryonic 
kidney cells were maintained in growth medium containing Dulbecco’s modified 
Eagle’s medium (DMEM) and 5% fetal bovine serum (FBS). Recombinant parental 
(H5N3) and NS1 mutant (H5N3/NS1/144) viruses were generated from A/Ck/TX/02 
(H5N3) virus by the eight plasmid reverse genetics technique (8). H5N3/NS1/144 
expresses the first 144 amino acids of the NS1 protein compared to the full length (230 
amino acids) of the parental H5N3 virus. Viral stocks for H5N3 and H5N3/NS1/144 
viruses were generated in 10 and 7 day-old embryonated chicken eggs, respectively. 
Viruses were titrated and the embryo infectious dose 50 (EID50) was determined by the 
Reed and Muench method (Reed & Muench, 1938).  
2.2.2 Cloning of A/Chicken/TX/02 H5N3 Genes for Reverse Genetics 
To clone full-length genes of A/Ck/TX/02 (H5N3), viral RNA was isolated from 
200 µl allantoic fluid with the RNeasy-Kit (Qiagen, Valencia, CA), according to the 
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manufacturer’s instructions.  First strand cDNA of all eight vRNA segments was 
synthesized using Uni12 primer (Hoffmann et al., 2001) and OmniProII RT (Promega, 
Madison, WI) reverse transcriptase as per manufacturer’s instructions.  Individual viral 
segments were PCR amplified using PFU-Ultra polymerase (Stratagene, La Jolla, CA) 
and segment specific primers as previously described (Hoffmann et al., 2001).  PCR 
products were cloned into pCRBlunt (Invitrogen, Carlsbad, CA) and sequenced. A 
plasmid (pDualPol) containing a RNA polymerase I promoter and terminator sequence 
flanked by a RNA polymerase II promoter and polyadenylation signal was generated as 
previously described (Chin et al., 2002). Once transferred to the pDualPol vector, the 
correct orientation of the viral cDNAs was confirmed by sequencing. H5N3/NS1/144 
was generated by inserting an oligonucleotide containing an AscI restriction site and stop 
codons in all three open reading frames (TAGCTAGGCGCGCCTAGCTA) at the PshAI 
restriction site (nt 430) of the NS segment cDNA (Figure 1). This insertion resulted in 
the disruption of the carboxy terminal half (145-230 amino acids) of the NS1 protein 
maintaining intact the coding region of NEP.  
2.2.3 Recovery of Viruses Using Reverse Genetics 
Infectious H5N3 and mutant H5N3/NS1/144 viruses were generated as 
previously described (Hoffmann et al., 2000) with some modifications. Briefly, 293-T 
cells and CEF were co-cultured at 1:1 ratio in a six well plate. After 24 hours, the cell 
culture media was replaced with 2 ml of OptiMEM supplemented with 2% FBS. Cells 
were transfected with 333 ng of each of the 8 plasmids mixed with 9 µl of Trans IT 
(Mirrus, Madison, WI) transfection reagent. Twenty four hours post transfection, the 
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media was changed to OptiMEM supplemented with 0.15% FBS and 1% BSA followed 
24 hours later with OptiMEM supplemented with 0.15% FBS 1% BSA and 0.0005 
µg/ml of TPCK trypsin. Seventy-two hours post transfection, 100 µl supernatant of 
H5N3 and H5N3/NS1/144 transfected cells was used to inoculate 10 and 7-day old 
specific pathogen free (SPF) embryonated chicken eggs, respectively. Viral stocks for 
samples positive for virus, as determined by HA, were further generated in SPF 
embryonated chicken eggs and titers determined as EID50/ml. 
2.2.4 Viral Growth Kinetics  
Comparison of H5N3 and H5N3/NS1/144 viral growth kinetics was carried out 
in interferon competent A-CEC and in embryonated chicken eggs at different age in 
development. A-CECs were generated by aging freshly prepared CEF for 10 days as 
previously described (Sekellick & Marcus, 1986). A-CEC plated in 60 mm dishes were 
infected with either H5N3 or H5N3/NS1/144  at a multiplicity of infection (MOI) of 
0.001 in DMEM media supplemented with 0.0005 µg/ml of TPCK trypsin, and cell 
culture supernatants were collected every 24 hours for five days. Virus titrations were 
carried out in DF1 cells and expressed as plaque forming units (PFU/ml). To study 
growth kinetics in embryonated chicken eggs, 100, 10, and 1 PFUs were inoculated into 
6 and 13 day old embryonated chicken eggs, via the chorioallantoic sac route. Embryos 
were observed daily for mortality, up to 5 days post-inoculation, and allantoic fluid from 
dead embryos was assessed for HA activity. 
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2.2.5 Plaque Assay  
Confluent monolayers of DF-1 cells in 6 wells were infected with 10-fold serial 
dilutions of infected A-CEC supernantants. After adsorbing the virus at 37°C for 1 h, the 
infected cells were overlaid with 1% agarose in VP-SFM supplemented with 0.0005 
µg/ml of TPCK trypsin and were incubated at 37°C for 48 hours. Plates were then fixed 
overnight with 10% buffered formalin, stained with 1% crystal violet, plaques counted 
and virus titer expressed as PFU/ml. 
2.2.6 Quantification of IFN-ß mRNA by Real-Time RT-PCR 
The relative levels of IFN-ß m-RNA produced by chicken cells in response to 
H5N3 and H5N3/NS1/144 virus infection was evaluated. Briefly, A-CEC were infected 
with H5N3 and H5N3/NS1/144  viruses at an MOI of 0.001 and 24 hours post infection, 
cells were trypsinized and total RNA isolated using the Ambion 4PCR RNA extraction 
kit (Ambion, Austin, TX) as per manufacturer’s instructions.  cDNA was synthesized 
from purified mRNA with poly(dT) primer (Ambion, Austin, TX) and Superscript II 
reverse transcriptase (Ambion, Austin, TX) and measured by real-time PCR analysis 
using primers specific for chicken IFN-ß (Forward 5’ 
AGCTCTCACCACCACCTTCTCCT 3’ and Reverse 5’ 
TGGCTGCTTGCTTCTTGTCCTT 3’) in an iCycler (BioRad Laboratories, Hercules, 
CA) for 40 cycles. Expression of chicken ß-actin mRNA was used to normalize cellular 
RNA levels between samples (Primers: Forward 5’ 
TATTGTGATGGACTCTGGTGATG 3’ and Reverse 5’ TCGGCTGTGGTGGTGAAG 
3’) using standard procedures (Quinlivan et al., 2005). 
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2.2.7 Experimental Design for Challenge Study Using Live H5N3/NS1/144 Vaccine 
Two groups of 15 six-week-old Hyline chickens were inoculated by the intra-
tracheal and intranasal routes with 0.2 ml of 106 EID50/ml of H5N3 or H5N3/NS1/144 at 
6-weeks of age. The immunized chickens were then challenged 4-weeks post 
immunization with 0.2 ml of 106 EID50/ml H5N3 virus via the intra-choanal and 
intranasal route. Four days post immunization and post challenge five chickens from 
each group were euthanized and tracheal swabs collected for virus re-isolation and 
estimation of virus load. Virus re-isolation was performed in 8-day-old chicken embryos. 
Virus replication was determined by real-time RT-PCR for influenza matrix gene using 
AgPath-ID™ AIV- M kit (Ambion, Austin, TX) as per manufacturers instructions. 
Trachea and lung samples were collected for histopathological studies. All chickens 
were bled at 1,2 3, and 4 weeks post-immunization and sera was tested for presence of 
antibodies against NP using a commercial ELISA kit (Synbiotics Inc., San Diego, CA), 
HA using hemagglutinin inhibition test  and NS1 using Western blot analysis. 
2.2.8 Assessing Stability and Safety of H5N3/NS1/144 Vaccine as a Live Attenuated 
Vaccine 
The stability and safety of the live H5N3/NS1/144 virus as a live vaccine was 
assessed by five back passages in 6-8 week old chickens. Three different lineages with 
one chicken per back passage were used to determine the reproducibility of the results. 
Briefly, three 6-week old chickens were inoculated intra-tracheally with 106.0 EID50 and 
four days post inoculation tracheal swabs were collected in 2 ml DMEM and chickens 
euthanized and examined for lesions. One hundred µl of tracheal swab sample was used 
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to infect one chicken and this process was repeated five times. Two hundred µl of 
tracheal swabs fluid was used to extract viral RNA using the RNA Mag Max kit 
(Ambion Inc, Austin, TX) as per manufacturer’s instructions. Viral cDNA was prepared 
using Uni-12 primer (reference) and MLV-RT (Ambion, Austin, TX) and full length NS 
viral gene was PCR amplified using PFU-Ultra polymerase (Stratagene, La Jolla CA) 
and segment specific primers as previously described (Hoffmann et al., 2002).  PCR 
products were separated on a 1% agarose gel in TAE, gel purified using PurelLinkTM 
Quick Gel Extraction Kit (Invitrogen, Carlsbad CA), cloned into pCRBluntTM vector 
(Invitrogen, Carlsbad CA) and sequenced. 
2.2.9 Preparation of Killed Vaccine 
Seed stocks of H5N3 and H5N3/NS1/144 viruses were propagated in thirty 10- 
and 7-day-old embryonated chicken eggs, respectively. Allantoic fluid was collected 
from embryos that died between 48-120 hours post inoculation, and tested for HA 
activity and bacterial contamination. Based on HA titers, allantoic fluids from embryos 
infected with a particular virus were pooled together and virus stock was inactivated by 
adding beta-propiolactone (BPL) at a ratio of 1:2000 (vol/vol) and allowing the fluid to 
remain at room temperature for 4 h followed by 24 h at 4°C. Inactivated virus was then 
concentrated by ultracentrifugation through a 30% sucrose cushion at 4°C for 1 h at 
27,000 xg. Viral pellets were then resuspended and sonicated in appropriate volumes of 
STE buffer (10 mM Tris-HCl, pH 8.0, 0.1 M NaCl, 1 mM EDTA). Inactivation of the 
virus stocks was confirmed by the absence of detectable infectious virus upon passage of 
the treated and concentrated allantoic fluid in 7 day-old embryonated chicken eggs. HA 
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titers of the vaccine stocks were standardized to 128 HA units. Inactivated viruses were 
then emulsified in mineral oil as described by Stone et.al, (Stone, 1987; Stone et al., 
1983) prior to vaccination. 
2.2.10 Experimental Design for Challenge Study Using Killed H5N3/NS1/144 Vaccine   
Groups of 10 chickens were vaccinated, at three weeks of age, subcutaneously in 
the nape of the neck with 0.5 ml (128 HA units) of either H5N3 or H5N3/NS1/144 killed 
viruses. Vaccinated chickens were boosted with second dose two weeks later by the 
same method and route. Two weeks later (seven weeks of age), chickens were 
challenged with 0.2 ml of 106 EID50/ml parental H5N3 virus via the 
intrachoanal/intranasal route and observed for clinical signs of disease up to 7 days post 
challenge. Four days post challenge all chickens were euthanized and tracheal swabs 
collected for virus re-isolation in 8-day-old embryonated chicken eggs. In addition, virus 
replication at four days post challenge was determined by real-time RT-PCR for 
influenza matrix gene using AgPath-ID™ AIV- M kit (Ambion, Austin, TX) as per 
manufacturers instructions.  Chickens were bled at 1, 2, 3 and 4 weeks post vaccination 
and sera tested for presence of antibodies against NP using a commercial ELISA kit 
(Synbiotics Inc.) and HA using hemagglutinin inhibition test . 
2.2.11 SDS-PAGE and Western Blot Analysis  
The immune response to NP and NS1 proteins in chickens vaccinated with H5N3 
and H5N3/NS1/144 viruses was examined by Western blot analysis. Briefly, baculovirus 
expressed and purified NP and NS1 proteins (10.5 ng of /lane) (Watson et al., 2008) 
were separated in 12% SDS-PAGE gels and transferred to an Immobilon-P membrane 
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(Millipore, Billerica, MA).  Serum samples were diluted 1:35 in 5% non-fat dry milk in 
PBS and incubated on the membrane at room temperature for 1 h.  Membranes were 
washed 3 times/5 min each with PBST (PBS. 0.05% Tween 20) and then incubated with 
1:1,000 dilution of rabbit anti-chicken HRP labeled secondary antibody (Bethyl 
Laboratories, Montgomery, TX).  Membranes were incubated 1 h at room temperature 
and washed three times before adding TMB membrane substrate (KPL, Gaithersburg, 
MD). 
 
2.3. Results 
2.3.1 Viral Growth in Embryonated Chicken Eggs  
To assess viral growth in interferon incompetent and competent systems, ten, 6- 
and 13-day-old eggs respectively, were inoculated with 1, 10 and 100 PFU of H5N3 or 
H5N3/NS1/144 viruses. Viral growth was measured in terms of embryo mortality and 
was confirmed by HA activity in the allantoic fluid of dead embryos. Interestingly, in 6-
day-old embryonated chicken eggs, H5N3/NS1/144 grew better than parental H5N3 
virus. However, in 13-day-old embryonated chicken eggs, H5N3/NS1/144 virus 
replication was significantly impaired when compared to H5N3 as shown in Fig. 2.  
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Fig. 2. Characterization of viral growth in embryonated chicken eggs (ECE). (a) The 
allantoic cavities of 6-day-old (A)and 13-day-old (B) embryonated eggs were infected 
with 100, 10 and 1 plaque forming units (PFUs) of the recombinant viruses. The infected 
ECE were examined for mortality upto 5 days post inoculation and represented as 
percent dead.  
 
 
 
2.3.2 H5N3/NS1/144 Replication is Impaired in A-CEC 
In order to investigate the multi-step growth properties of H5N3/NS1/144 and 
H5N3 viruses in interferon competent A-CEC, confluent monolayers of A-CEC were 
infected at a low MOI (MOI = 0.001) in media supplemented with trypsin (0.0005 
µg/ml). Supernatants from infected cells were collected at different time points post-
infection (24, 48, 72 and 96 h) and virus titers determined by plaque assay on DF1 cells. 
Like in interferon competent 13-day-old ECE, replication of H5N3/NS1/144 virus in A-
CEC was significantly reduced compared to H5N3 as shown in Fig. 3.  
 
A B 
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Fig. 3. Characterization of viral growth in aged chicken embryo cells (A-CEC). A 
comparison of viral growth was done for the recombinant viruses in A-CEC cells. A-
CEC cells were infected with each of the viruses at an MOI of 0.001. Viral titers in 
infected cell culture supernatants were determined at the indicated times post-inoculation 
by plaque assay on DF1 cells. 
 
 
 
2.3.3 Interferon Induction by H5N3/NS1/144  
The NS1 protein of influenza virus has previously been shown to act as an 
interferon-α/ß antagonist (Cauthen et al., 2007; Egorov et al., 1998; Garcia-Sastre et al., 
1998). To determine whether the induction of antiviral state in A-CEC infected with 
H5N3/NS1/144 and H5N3 correlates with the level of IFN-ß induction, relative levels of 
IFN-ß mRNA in the infected cells was quantitated by real-time RT-PCR at 24 hours post 
infection. As shown in Fig. 4, H5N3/NS1/144 appears to induce significantly higher 
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levels of interferon than parental H5N3 virus. These results reflect the inability of 
H5N3/NS1/144 to induce anti-interferon activity in interferon competent systems. 
 
 
Fig. 4. Quantification of IFN-ß mRNA synthesis by A-CEC infected with H5N3, 
H5N3/NS1/144, at MOI of infection 0.001. Twenty-four hours post infection, cells were 
collected, RNA extracted and IFN-β mRNA expression determined by real-time RT-
PCR. The results represent relative IFN-β mRNA levels normalized with levels of β-
actin mRNA.  
 
 
2.3.4 Efficacy of H5N3/NS1/144 Virus as a Live Attenuated Vaccine 
Attenuation of H5N3/NS1/144 was based on lesions and virus isolation from 
immunized chickens.  On the other hand, efficacy of H5N3/NS1/144 virus as a live 
vaccine was evaluated based on protection against homologous, H5N3 challenge. 
Chickens immunized with H5N3 but not with H5N3/NS1/144 virus showed gross 
lesions 4 days post inoculation. Lesions observed with H5N3 were tracheal plugs and 
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inflammation of the trachea. Histologically, severe lymphocytic and mononuclear 
infiltration was observed in chickens immunized with H5N3 but not with 
H5N3/NS1/144. Virus replication was demonstrated by virus re-isolation from tracheal 
swabs of chickens immunized with both H5N3 and H5N3/NS1/144  viruses  as shown in 
(Table 1). In addition, virus quantification, in terms of Ct values from real-time RT-PCR 
of viral RNA isolated from swab samples, indicated that H5N3/NS1/144 was 
significantly attenuated in its replication.  
 
 
Table 1. Lesions and virus shedding in chickens vaccinated with live virus vaccines and 
challenged with 105 EID50 of H5N3 virus. Tracheal swabs were collected for virus re-
isolation and lung and tracheal sections were collected for histopathology 4 days post 
immunization and 4 days post challenge.  
 
 
Vaccine Group 4 dpi* 4 dpc** 
 Gross Lesions 
Virus 
Re-
isolation 
Viral RNA 
Levels*** 
Gross 
Lesions 
Virus 
Re-
isolation 
Viral RNA 
Levels*** 
H5N3/NS1/144 0/5 4/5 35.2 (±5.0) 0/5 3/5 35.6 (±3.2) 
H5N3 5/5 5/5 25.4 (±0.5) 0/5 0/5 > 40 
Challenge 
Control    5/5 5/5 23.7 (±0.9) 
Negative 
Control 0/5 0/5 > 40 0/5 0/5 > 40 
*dpi = days post immunization 
**dpc = days post challenge 
*** RNA levels represented by Ct values. Numbers in parentheses represent standard 
deviation of mean 
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Fig. 5. H&E staining of lung sections of, rH5N3 and rH5N3/NS1/144 immunized (upper 
panel) and immunized and challenged (lower panel) chickens. Lungs of rH5N3 
immunized chickens show severe lymphocytic and mononuclear infiltration with 
heterophilic inflammation 4 days PI. Similar lymphocytic and mononuclear infiltration is 
observed in lungs of rH5N3/NS1-144 immunized chickens 4 days PI but to a much 
lesser degree while the heterophilic infiltration appears to be absent. On the other hand, 
only slight lymphocytic infiltration was observed in chickens immunized with rH5N3 
and H5N3/NS1-144 and challenged with H5N3. 
 
 
Protection conferred by H5N3/NS1/144 and H5N3 viruses at four weeks post 
immunization, was compared and measured based on the amount of virus shedding and 
protection from gross and histo-pathological lesions at 4 days post challenge with H5N3 
virus. No gross lesions were observed in the H5N3 and H5N3/NS1/144 immunized 
chickens when challenged with H5N3 virus; however, minor histo-pathological lesions 
were observed only in the lungs of H5N3/NS1/144 vaccinated chickens as seen in Fig. 5. 
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We were unable to re-isolate any challenge virus from chickens previously immunized 
with H5N3. However, 3 out of 5 chickens that received the H5N3/NS1/144 live vaccine 
were positive for virus re-isolation when tested in embryonated chicken eggs.  These 
results were confirmed by real time RT-PCR of viral RNA isolated from tracheal swabs 
collected at 4 days post inoculation in H5N3 and H5N3/NS1/144 vaccinated chickens. 
Additionally, to assess protection, serum samples were collected every week for 4 weeks 
post vaccination to monitor antibody response. Significantly stronger immune response 
was observed in chickens vaccinated with H5N3 compared to H5N3/NS1/144 at one 
week post-vaccination based on HI and NP antibody titers. However, at 2, 3, and 4 
weeks, post-vaccination the antibody response induced by H5N3/NS1/144 was not 
significantly different from H5N3 as shown in Fig 6. 
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Fig. 6. Antibody levels (NP and HA) in live-vaccinated chickens. Serum samples were 
collected weekly after vaccination. Serological response was estimated based on log10 of 
average value of the HI titers and antibody titers against NP protein. 
 
 
2.3.5 Safety of H5N3/NS1/144 Virus as a Live Attenuated Vaccine 
To ensure the safety of H5N3/NS1/144 as a live attenuated vaccine, the virus was 
back passaged for 5 rounds in three independent lineages of 6-8 week old chickens. 
Interestingly, after two rounds of passage, lesions similar to those induced by H5N3 
virus were noticed in the trachea and lungs of infected chickens. After five rounds of 
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passage, the stability of the NS gene was determined by RT-PCR amplification of 
genome segment 8 RNA extracted from tracheal swabs.  It was interesting to see that 
various truncated forms of genome segment 8, were isolated from each of the 3 chickens 
tested. Upon sequencing it was evident that in lineages 1 and 2, a region containing three 
amino acids before and one amino acid after the stop codon were deleted (amino acid 
142-145), resulting in an NS1 ORF protein with an internal deletion of only four amino 
acids compared to the parental H5N3 NS1 ORF. In lineage 3, a mixed population of 
different size gene segment 8 was detected Fig. 7; in one of the NS genes sequenced 
(L3a) only the stop codon was deleted, resulting in an ORF encoding the entire 230 
amino acids NS1 protein. However, in another sequenced gene (L3b), 57 amino acids, 
from position 80-136, were deleted resulting in a truncated NS1 protein expressing only 
87 amino acids. Since viruses from all three lineages showed increased pathogenicity, 
which correlated with the loss of the stop codon and/or the generation of deletions, we 
conclude that the H5N3/NS1/144 virus is unstable and reverted to virulence in chickens.  
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Fig.7. NS1 ORF after back passage of H5N3/NS1/144 in 6-8 week old chickens. A. 
Agarose gel electrophoresis of RT-PCR products of the NS gene segment of 
H5N3/NS1/144 after 5 rounds of back passage in chickens. PCR products for parental 
H5N3, NS1 mutant H5N3/NS1/144 and passage viruses from three different lineages 
(L1, L2 and L3) are shown. B. Schematic representation of the deletion (light colored 
regions) and point mutations in each of the three passage lineages (L1, L2 and L3) of 
H5N3/NS1/144 in chickens.  
 
A 
B 
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2.3.6 Efficacy of H5N3/NS1/144 as a Killed Vaccine 
Killed vaccines were prepared from H5N3 and H5N3/NS1/144 virus stocks as 
described in Material and Methods and the level of protection was compared based on 
HI antibody titers and re-isolation of challenge virus from vaccinated chickens. Four 
days post challenge tracheal swab samples were taken from all chickens for virus re-
isolation and viral RNA detection. Virus was re-isolated from tracheal swabs from 2/10 
chickens immunized with H5N3/NS1/144 vaccinated while no virus was re-isolated 
from H5N3 vaccinated chickens as shown in table 2.  
 
 
Table 2. Virus re-isolation and viral RNA detection in tracheal swabs of chickens 
vaccinated with killed H5N3 and H5N3/NS1/144 viruses and challenged with H5N3 1 
week post boost.  
 
Vaccine Group 4 dpc* 
 Gross 
Lesions 
Virus 
Re-
isolation 
Viral RNA 
Levels** 
H5N3/NS1/144 0/10 2/10 32.3 (±3.75) 
H5N3 0/10 0/10 33.3 (±3.45) 
Challenge Control 6/10 10/10 22.6 (±3.66) 
Negative Control 0/10 0/10 > 40 
* dpc = days post challenge 
** expressed as Ct values as determined by Real-time RT-PCR using the AgPath-ID™ 
AIV-M Ambion kit 
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However, when viral RNA levels were compared by real time RT-PCR, no 
significant difference between the two vaccinated groups was noticed. Antibody titers, 
determined by HI and NP specific ELISA (Synbiotics Inc, San Diego, CA), were not 
detected at 1 week post vaccination with either vaccine, but were detected at 2 weeks 
post vaccination and steadily increased after booster vaccination with no significant 
differences observed between H5N3/NS1/144 and H5N3 vaccinated groups as shown in 
Fig. 8. 
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Fig 8. Antibody levels (NP and HA) in killed-vaccinated chickens. Chickens were 
vaccinated at 2 weeks of age and 2 weeks post vaccination chicken were boosted. Serum 
samples were collected weekly after vaccination. Serological response was estimated 
based on log10 of average value of the HI titers and antibody titers against NP protein. 
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2.3.7 Differentiation between Vaccinated and Infected Chickens 
Presence of antibodies to NS1 protein in chickens vaccinated with live H5N3 and 
H5N3/NS1/144 was determined by Western blot analysis.  As shown in Fig.9, chickens 
vaccinated with live H5N3 virus produced antibodies against NS1 protein while 
antibodies were absent or detected at very low levels, in chickens vaccinated with live 
H5N3/NS1/144. By comparison, antibody levels to NP were detected to similar levels in 
chickens vaccinated with live H5N3 and H5N3/NS1/144 viruses.  
 
 
 
Fig. 9. Antibody response to rH5N3 and rH5N3/NS1-144 viruses.  Western blot analysis 
of purified rNP, rNS1 and rM1 proteins using sera obtained from chickens inoculated 
with H5N3 (1, 2, 3 and 4) or rH5N3/NS1-144 (5, 6, 7 and 8) at 1, 3 and 4 weeks post 
vaccination.  10.5 ng of purified protein was loaded per lane.  Chicken sera samples 
were diluted at 1:35. 
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2.4 Discussion 
The increasing number of AI outbreaks worldwide highlights the difficulties 
encountered in controlling this disease. As a result, vaccination, which has rarely been 
used in the past, has become a recommended tool to support eradication efforts and to 
limit increasing economic losses due to AI.  However, due to trade implications and the 
common use of serology in AI surveillance programs in commercial poultry, traditional 
vaccine strategies are not feasible and vaccines with DIVA properties have been 
recommended by international health organizations. Vaccines with DIVA properties 
have successfully been used to control AIV outbreaks (Capua et al., 2002; Cattoli et al., 
2003; Lee et al., 2004). To date the DIVA system that has been effectively used is based 
on heterologous vaccination, where the vaccine is made with a virus possessing the same 
hemagglutinin as the field virus and a neuraminidase of a different subtype. Although 
both HA and NA contain neutralizing epitopes, antibodies against HA are more 
important in protection (Suarez, 2005). As a result, vaccinating with a homologous HA 
subtype but a NA different to that of a circulating AI strain provides protection and at 
the same time makes it possible to differentiate between vaccinated and infected 
chickens.  This strategy has been proven to be very effective in AIV outbreaks in 
chickens (Capua et al., 2002), however it limits the number of potential effective vaccine 
candidates that can be selected since inclusion of the NA of the circulating viruses have 
shown to be more protective compared to a heterologous NA vaccine. A DIVA system 
based on the NS1 protein has been proposed for AI (Tumpey et al., 2005). Targeting the 
NS1 protein enables the generation of attenuated vaccine viruses since NS1 is a 
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virulence factor due to its anti-interferon activity. This makes NS1 mutant viruses ideal 
candidates for a live attenuated vaccines with DIVA properties. In this study we 
evaluated the pathogenesis, protection and safety of such a LPAIV live vaccine 
candidate, which expresses a truncated NS1 protein (144 amino acids). 
To generate the NS1 mutant virus, we established a reverse genetics system for 
the LPAIV A/Ck/Texas/2002 H5N3 virus. The NS mutant gene segment was generated 
by insertion of an oligonucleotide, with stop codons in all 3 open reading frames, at 
amino acid position 144 of the NS1 gene. The recovered NS1 mutant virus, 
H5N3/NS1/144, was attenuated compared to parental H5N3 virus in terms of growth and 
pathogenicity in interferon competent system in vitro, in ovo and in vivo. It was expected 
that that older age embryos would provide more of a challenge for H5N3/NS1/144 
replication because the IFN-α/β system in older eggs is more mature (Sekellick et al., 
1990; Sekellick & Marcus, 1985). Consistent with previous studies, it was found that 
H5N3/NS1/144 virus was severely attenuated in comparison to the parental virus in 13-
day-old embryonated chicken eggs (Fig. 1). In contrast, embryo mortality caused by 
H5N3/NS1/144 was, higher in 6-day-old embryonated chicken eggs compared to 
parental H5N3 virus (Fig. 1). Attenuation was also observed, in terms of significantly 
lower titers, for H5N3/NS1/144 in A-CEC when compared to parental H5N3. The lower 
virus titers in A-CEC correlated with increased type I interferon induction as shown by 
significantly increased mRNA expression of IFN-β (Fig. 3). These results are in accord 
with the observations of studies carried out in mice, swine, equine and chickens in which 
the IFN-β inducing capacity of influenza viruses expressing truncated NS1 was elevated 
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and corresponded with decrease ability of the virus to replicate in interferon competent 
systems (Cauthen et al., 2007; Egorov et al., 1998; Quinlivan et al., 2005; Solorzano et 
al., 2005). H5N3/NS1/144, was also attenuated in chickens based on decreased virus re-
isolation and pathogenicity while still induced an antibody response to NP similar to 
parental H5N3 virus. HI titers were only slightly lower for H5N3/NS1/144 at 1, 3 and 4 
weeks post-vaccination when compared to parental H5N3 virus (Fig. 4). However, both 
groups of chickens were protected against lesions caused by homologous parental H5N3 
challenge. In addition, there was a significant reduction of challenge virus in the tracheal 
swabs of H5N3 and H5N3/NS1/144 vaccinated and challenge groups compared to the 
non-vaccinated challenge control group. This demonstrates, the ability of 
H5N3/NS1/144 to induce a good immune response, conferring protection against a 
homologous challenge. However, significantly lower levels of challenge virus were 
detected in chickens pre-immunized with H5N3 virus compared to H5N3/NS1/144. This 
difference in protection could be due to attenuation of H5N3/NS1/144, which results in 
reduced replication in target organs inducing a weaker overall (cell and antibody 
mediated) immune response compared to parental H5N3 virus.  
Immune sera of chickens inoculated with H5N3/NS1/144 displayed a high level 
antibody response against NP and HA proteins but below detectable levels of antibodies 
to NS1 (Fig. 8) making it possible to differentiate H5N3/NS1/144 vaccinated from 
H5N3 infected chickens.  
We also evaluated the safety and stability of H5N3/NS1/144 virus as a live 
vaccine by carrying out 5 back passages in 6-8 week old chickens, in triplicate. After 5 
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back passages in chickens, H5N3/NS1/144 underwent immune selection and the virus 
reverted to virulence causing lung lesions similar to those produced by parental H5N3 
virus. The NS gene segment of H5N3/NS1/144 was not stable and the engineered stop 
codon was deleted in all three, lineages, resulting in an almost full-length NS1 proteins. 
These results emphasize the importance of NS1 protein in pathogenesis of influenza 
viruses in interferon competent systems. Interestingly, passage lineage 3 also contained a 
truncated population of NS1 expressing only 87 amino acids.  It will be interesting to 
study the replication properties and pathogenesis of a recombinant H5N3 virus 
expressing only 87 amino acids of NS1.  Previous reports on the role of truncated NS1 
mutants in equine and swine influenza viruses (Quinlivan et al., 2005; Solorzano et al., 
2005) indicate that shorter forms of NS1 result in more stable proteins, ensuing in a 
more functional NS1 protein. In these studies, influenza viruses expressing shorter NS1 
proteins were attenuated compared to parental virus; however, these viruses were more 
virulent when compared to other NS1 mutant viruses expressing longer proteins. 
Interestingly, when a naturally truncated NS1 mutant LPAIV was serially passaged in 
older age embryonated chicken eggs, further truncations in the NS1 gene segment 
resulted in further attenuation (Wang et al., 2008). The differences observed in 
pathogenicity for viruses from the above mention study and the current study could be 
strain specific. The presence of an AIV population with a truncated NS1 ORF expressing 
87 amino acids, after serially passage in chickens suggests that AIVs with shorter NS1 
could have a selective advantage to help regain its virulence. However, the reversion of 
H5N3/NS1/144 to virulence in chickens cannot be fully attributed to the presence of an 
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87 amino acid protein since a population of viruses expressing a near full length NS1 
protein (with 4 amino acid deletion at position142-145) was also present. Further studies 
are needed to address the significance of different size NS1 mutant viruses in virulence 
in chickens. 
Though H5N3/NS1/144, used in this study was not stable and reverted to 
virulence during back passage in chickens, in a separate study (unpublished results) 
H5N3/NS1/144 infected chickens did not transmit the virus to uninfected cage-mates 
when compared to parental H5N3 infected chickens. The lack of natural transmission of 
H5N3/NS1/144 could restrict its circulation in chickens, precluding the possibility of 
reversion to virulence. It is possible that by deleting the carboxy-end of NS1 instead of 
inserting a stop codon we could avoid the reversion of virus to virulence. However, this 
is unlikely, since shorter NS1 proteins seem to be more stable and more functional, as 
demonstrated in other studies (Quinlivan et al., 2005; Solorzano et al., 2005). 
Consequently, more comprehensive studies are needed to characterize mutant viruses 
with shorter NS1 proteins. Alternatively, to ensure no reversion to virulence, a killed 
vaccine made out of mutant viruses with shorter NS1 protein as seed virus, as shown in 
this study, would be a much safer and feasible option.  
The efficacy of parental H5N3 and H5N3/NS1/144 inactivated vaccines was 
tested against a homologous, H5N3 virus challenge. Virus shed was significantly 
reduced in chickens vaccinated with either killed vaccines and no significant difference 
in terms of antibody titers was observed between the two vaccinated groups (Table 2).  
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In summary, AIV vaccines with a truncated NS1 protein could be used to 
differentiate between vaccinated and infected chickens making DIVA strategy a feasible 
option. The NS1 mutant AIV generated in this study was highly effective as killed 
vaccine. However, its use as live virus raises safety concern, because back passage in 
chickens, resulted in reversion back to virulent phenotype. The future development of 
live NS1 mutants can only be feasible by identifying mutants that are unable to revert 
back and by developing mutant viruses unable to regain the wild type gene segment 
through re-assortment.  
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CHAPTER III 
 
CHARACTERIZATION OF NS1 MUTANT AVIAN INFLUENZA VIRUSES TO 
GROW IN INTERFERON COMPETENT SYSTEMS 
 
3.1 Introduction 
Influenza A viruses are members of the Orthomyxoviridae family and their 
genome consists of eight single-stranded, negative sense RNA segments which encode 
11 different proteins (PB2, PB1, PB1-F2, PA, HA, NP, NA, M1, M2, NS1, and NS2) 
(Chen et al., 2001). Influenza A viruses are classified into subtypes based on their 
envelope proteins, hemagglutinin (HA) and neuraminidase (NA). Currently, 16 HA and 
9 NA subtypes have been identified. Wild birds serve as reservoirs to all subtypes of 
influenza A viruses and transmission of these viruses to domestic poultry and their 
adaptation to the new host is well established (Swayne, 2007). Some of the avian 
influenza virus (AIV) subtypes, such as H5 and H7, which spread into domestic 
chickens, have shown to turn into highly pathogenic viruses (Swayne, 2007). Better 
understanding of AIV virulence factors is likely to help, generate safe and efficacious 
vaccines and design better intervention strategies. Besides HA, NA and proteins of the 
polymerase complex, the non-structural protein NS1 is also an important virulence factor 
(Ito et al., 2001; Stephenson et al., 2004). NS1 inhibits and resist innate antiviral 
immune response through several different mechanisms and at different stages of 
induction. These mechanisms have been elucidated using both artificial and natural 
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truncations as well as point mutations in the NS1 gene segment as reviewed by Hale 
et.al. (Hale et al., 2008b).  
NS1 protein consist of two domains an RNA binding domain and an effector 
domain. The RNA binding domain of the NS1 protein has been shown to play a crucial 
role in inhibiting host interferon response through its ability to bind to the replicative 
forms of viral RNA. Arginine at position 38 and lysine at position 41 within the RNA 
binding domain are thought to directly interact with RNA, mediating binding. The main 
function of the carboxy-terminal 157 amino acids of the NS1 protein, which contain the 
effector domain (amino acids 134 to 161) (Nemeroff et al., 1995), is to stabilize and/or 
facilitate NS1 dimerization (Wang et al., 2002) and has binding sites for several cellular 
proteins such as cleavage and polyadenylation specificity factor (CPSF), and poly (A)-
binding protein II (PABII). The carboxy-terminal region of NS1 also contains a PDZ-
binding motif (Chen et al., 1999; Nemeroff et al., 1998; Obenauer et al., 2006), which 
directly or indirectly affects interferon induction. The presence of amino acid Glutamine 
(Q) at position 92 of NS1 in the H5N1/97 influenza viruses has been implicated in its 
ability to modulate the cytokine response and has been associated with the high 
virulence of these viruses in pigs. Recently, it was shown that the amino acid at position 
149 of NS1 in highly pathogenic avian influenza (HPAI)-H5N1 affected the ability of 
the virus to antagonize the induction of IFN α/β (Li et al., 2006). The valine to alanine 
mutation at position 149 caused increased expression of NS1 protein, which is believed 
to increase its ability to inhibit interferon, thereby making the virus more virulent in 
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chickens. This increase in virulence was demonstrated in terms of increased lethality in 
embryonated chicken eggs (ECE) and chickens. 
Phylogenetically, NS1 proteins of influenza viruses are divided into alleles A and 
B (Ludwig et al., 1991). Allele B includes exclusively NS1 proteins from avian viruses 
while allele A includes influenza viruses isolated from mammalian species.  As little as 
62% identity has been observed between alleles A and B (Hale et al., 2008b). Most of 
the functional studies of NS1 have been limited to laboratory strains and highly 
pathogenic H5N1 strain of AIV, both of which belong to allele A. Recent studies have 
also shown that NS1 of allele B presents anti-interferon activity in chickens (Cauthen et 
al., 2007). However, studies addressing the role of NS1 in the host-pathogen interaction 
between AIVs with allele B NS1 viruses and chickens are lacking.  
We have recently shown, that a recombinant H5N3 LPAIV expressing first 144 
amino acids of NS1 (H5N3/NS1/144) is attenuated with regards to growth and virulence 
when compared to parental virus (Brahmakshatriya VR, 2009). However, when 
H5N3/NS1/144 was propagated under innate immune pressure in older age ECE, further 
truncation of the NS1 gene segment occurred resulting in the expression of a NS1 
protein with only 87 amino acids. Upon sequencing, we detected two additional point 
mutations in the RNA binding domain (position, 40 and 73) of two of the lineage 
passages. Since the RNA binding domain is critical in the anti-interferon activity of NS1, 
we sought to determine the significance of the truncation and point mutations on the 
virulence of the virus. Using reverse genetics, two NS1 mutant viruses (H5N3/NS1/87 
and H5N3/NS1/87P) were generated and their biological characteristics determined in 
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ovo, in vitro and in vivo systems. Our studies show that the H5N3/NS1/87 and 
H5N3/NS1/87P viruses, showed increased virulence compared to H5N3/NS1/144 and 
this gain in virulence correlated with increased ability of the virus to inhibit interferon. 
 
3.2 Materials and Methods 
3.2.1 Cells and Viruses 
DF1, a chicken embryo fibroblast cell line, was cultured in Leibovitz and 
McCoy’s growth medium containing 5% fetal bovine serum (FBS). Chicken embryo 
fibroblasts (CEF), aged chicken embryo cells (A-CEC) and 293-T human embryonic 
kidney cells were propagated in growth medium containing Dulbecco’s modified 
Eagle’s medium (DMEM) and 5% FBS. Mardin-Darby Canine Kidney (MDCK) cells 
were propagated and maintained in Virus Production-Serum Free Media (VP-SFM) 
(Gibco, New York, USA). Recombinant parental (H5N3) and NS1 mutant viruses 
(H5N3/NS1/144, H5N3/NS1/87and H5N3/NS1/87P) (see description of viruses Sections 
3.2.2 and 3.2.3) were generated by the eight plasmid reverse genetics technique 
(Hoffmann et al., 2000).  
3.2.2 Cloning of A/Chicken/TX/02 H5N3 Genes for Reverse Genetics 
To clone full-length genes of A/Ck/TX/02/H5N3, viral RNA was isolated from 
200 µl allantoic fluid using the RNeasy-Kit (Qiagen, Valencia, CA), according to the 
manufacturer’s instructions. First strand cDNA of all eight vRNA segments was 
synthesized using Uni12 primer (Hoffmann et al., 2001) and OmniProII RT (Promega, 
Madison, WI) reverse transcriptase as per manufacturer’s instructions. Individual viral 
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segments were PCR amplified using PFU-Ultra polymerase (Stratagene, La Jolla, CA) 
and segment specific primers as previously described (Hoffmann et al., 2001).  PCR 
products were cloned into pCRBlunt (Invitrogen, Carlsbad, CA) and sequenced. A 
plasmid (pDualPol) containing a RNA polymerase I promoter and terminator sequence 
flanked by a RNA polymerase II promoter and polyadenylation signal was generated as 
previously described (Hoffmann et al., 2000; Reddy, 2006). Once transferred to the 
pDualPol vector, the correct orientation of the viral cDNAs was confirmed by PCR. 
H5N3/NS1/144, an NS1 mutant virus, which expresses the first 144 amino acids of the 
NS1 protein (Figure 1), maintaining intact coding region of NEP, has already been 
described in earlier chapter.  
3.2.3 Serial Passage of H5N3/NS1/144 in Older-Age-ECE 
Allantoic fluid of H5N3/NS1/144 virus was serially passaged in increasing age 
embryonated chicken eggs (ECE) as shown in Fig.10. Virus propagation in the chorio-
allantoic cavity of ECE was done as previously described  (Swayne, 1998). Three 
independent lineages (L1, L2 and L3) were carried for 15 passages and allantoic fluid 
was collected 72-96 hours post-inoculation for every passage.  
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Fig.10. Schematic for serial passage of H5N3/NS1/144 in older age ECE. 
 
 
The allantoic fluid collected was tested for HA activity and positive samples 
were diluted 10-3 or 10-4, before the next round of propagation in ECE. After the first 
passage, the diluted virus was passaged into 3-4 ECE however, allantoic fluid from only 
one embryo was passaged, and allantoic fluid from the other infected embryos of the 
same lineage were kept as a backup. At no point during the serial passage were the 
viruses from two different eggs or lineages pooled. After 15 rounds of serial passages in 
older age ECE, each lineage was subjected to three rounds of plaque purification and 
plaque-purified viruses were propagated in 13-day-old ECE. 
3.2.4 Viral RNA Extraction and NS1 Gene Specific Cloning and Sequencing 
Viral RNA was isolated from plaque-purified viruses propagated in 13-d-old- 
ECE using the RNA Mag Max kit (Ambion Inc, Austin, TX) as per manufacturer’s 
instructions. Viral cDNA was prepared using Uni-12 primer (Hoffmann et al., 2001) and 
MLV-RT (Ambion, Austin, TX) and full length NS viral gene was PCR amplified using 
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PFU-Ultra polymerase (Stratagene, La Jolla CA) and segment specific primers as 
previously described (Hoffmann et al., 2001).  PCR products were separated on a 1.5% 
agarose gel in TAE, gel purified using PurelLinkTM Quick Gel Extraction Kit 
(Invitrogen, Carlsbad CA), cloned into pCRBluntTM vector (Invitrogen, Carlsbad CA) 
and sequenced. 
3.2.5 Recovery of Viruses Using Reverse Genetics 
Infectious parental (H5N3) and NS1 mutant viruses (H5N3/NS1/144, 
H5N3/NS1/87 and H5N3/NS1/87P) were generated as described by Hoffman et.al. 
(Hoffmann et al., 2000). Briefly, 293-T cells and chicken embryo fibroblasts were co-
cultured (1:1 ratio) in a six well plate. After 24 hours, the cell culture media was 
replaced with 2 ml of OptiMEM supplemented with 2% FBS. Cells were transfected 
with 333 ng of each plasmid mixed with 9 µl of Trans IT (Mirrus, Madison, WI) 
transfection reagent. Twenty-four hours post transfection, the cell culture media was 
changed to OptiMEM supplemented with 0.15% FBS and 1% BSA followed 24 hours 
later with OptiMEM supplemented with 0.15% FBS 1% BSA and 0.0005 µg/ml of 
TPCK trypsin. Seventy-two hours post transfection, 100 µl supernatant of H5N3, 
H5N3/NS1/87 and H5N3/NS1/87P transfected cells were inoculated into 10- day-old 
specific pathogen free (SPF) ECE while H5N3/NS1/144 was propagated in 7-day-old 
ECE. Viral stocks for recombinant viruses, were further generated in 10 or 7-day-old 
SPF ECE and virus titers were determined by plaque assay in DF1 cells and expressed as 
plaque forming units per ml (PFU/ml). 
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3.2.6 Viral Growth Kinetics  
Comparison of the growth kinetics of H5N3, H5N3/NS1/87 and H5N3/NS1/87P 
viruses was carried out in DF1 and A-CEC. A-CECs were generated by aging primary 
chicken cells, obtained from 10-day old embryos, for 10 days as described earlier 
(Sekellick & Marcus, 1985). A-CEC plated, in 60 mm dishes were infected with either 
H5N3, H5N3/NS1/144, H5N3/NS1/87 or H5N3/NS1/87P at a multiplicity of infection 
(MOI) of 0.001 in DMEM media supplemented with 0.0005 µg/ml of TPCK trypsin. 
Cell culture supernatants were collected every 24 hours for five days in case of A-CEC 
and for 3 days in case of DF1 cells. Virus titers in the collected supernatants was 
determined by plaque assay in DF1 cells and determined as PFU/ml. 
3.2.7 Plaque Assay  
Confluent monolayers of DF-1 or MDCK cells in 6 well plates were infected 
with 10-fold serial dilution of infected A-CEC supernatants or viral stocks generated in 
ECE. After adsorbing the virus at 37°C for 1 h, the inoculum was removed and the 
infected cells were overlaid with 1% agarose in VP-SFM supplemented with 0.0005 
µg/ml of TPCK trypsin and incubated at 37°C for 48 hours. Plates fixed over night with 
10% buffered formalin, stained with 1% crystal violet, plaques counted and virus titer 
determined as PFU/ml. 
3.2.8 Mean Death Time (MDT) and Embryo Death Percent (EDP) in Different Ages of 
ECE  
The pathogenicity of H5N3, H5N3/NS1/87 and H5N3/NS1/87P viruses was 
examined by determining mean death time (MDT) and embryo death percent (EDP) in 7, 
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10 and 13-day-old ECE. To determine MDT and EDP, groups of twenty, 7- and 10-days-
old ECE and twenty-five 13-day-old ECE, were inoculated via the chorioallantoic sac 
route with 102 PFUs of each virus or sham inoculated with phosphate-buffered saline 
(PBS). Embryos were then candled at 8-hour intervals for 6 days, embryo mortality 
recorded and presence of virus in dead embryos was confirmed by HA. Based on the 
number of ECE dead and time of death post inoculation, MDT was calculated as 
follows: the total sum of the product of, number of dead embryos at each time point and 
the time point in hours divided by the total number of dead embryos in that group 
(Perdue et al., 1990). 
3.2.9 Quantification of IFN-ß mRNA by Real-Time RT-PCR 
The relative levels of IFN-ß m-RNA produced by chicken cells in response to 
replication of H5N3, H5N3/NS1/144, H5N3/NS1/87 and H5N3/NS1/87P viruses were 
evaluated. Briefly, A-CECs were infected with H5N3, H5N3/NS1/144, H5N3/NS1/87 or 
H5N3/NS1/87P at an MOI of 0.01, 0.001 and 0.0001. Six hours post infection, cells 
were trypsinized and total RNA was isolated using the Ambion 4PCR RNA extraction 
kit (Ambion, Austin, TX) as per manufacturer’s instructions.  cDNA was synthesized 
from mRNA with poly(dT) primer (Ambion, Austin, TX) and Superscript II reverse 
transcriptase (Ambion, Austin, TX) and levels of IFN-ß mRNA expression determined 
by real-time PCR analysis using primers specific for chicken IFN-ß (Forward 5’ 
AGCTCTCACCAC CACCTTCTCCT 3’ and Reverse 5’ TGGCTGCTTGCTTCTTG 
TCCTT 3’) in an iCycler (BioRad Laboratories, Hercules, CA) for 40 cycles. Expression 
of chicken ß-actin mRNA was used to normalize cellular RNA levels between samples 
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(Primers: Forward 5’ TATTGTGATGGACTCTGGTGATG 3’ and Reverse 5’ 
TCGGCTGTGGTGGTGAAG 3’), using a standard procedure (Jaini et al., 2006). 
Relative quantitation of mRNA expression was calculated as fold increase in inoculated 
versus mock-inoculated control A-CEC. 
3.2.10 In Vivo Characterization of NS1 Mutant Viruses 
The virulence of the NS1 mutant viruses was further examined by comparing 
virus growth of H5N3, H5N3/NS1/144, H5N3/NS1/87 and H5N3/NS1/87P viruses in 1-
day-old chickens. Five groups of twenty, 1-day-old commercial layer-type Hyline 
chickens were inoculated by the intranasal/intrachoanal route with 0.1 ml containing 104 
PFU of parental or NS1 mutant viruses. Five contact control chickens were introduced 
into the same cage one day post-infection. The chickens were observed daily for clinical 
signs of disease and four days post-inoculation all inoculated chickens were euthanized 
and observed for gross lesions. Lung samples were collected in tubes containing 1 ml 
tryptose phosphate broth to determine viral titers in terms of PFU/ml in DF1 cells and 
EID50/ml in ECE. To assess the ability of the viruses to transmit, contact chickens were 
bled two weeks after exposure to virus-inoculated chickens and were checked for sero-
conversion using a commercially available NP ELISA kit for avian influenza 
(Synbiotics, San Diego, CA).  
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3.3 Results 
3.3.1 Immune Pressure Result in Genotypic Differences in NS1 
After serial passage of H5N3/NS1/144 in older age ECE, the virus was adapted 
to grow in 13-day-old ECE. This serial passage caused selection of NS gene segments 
with a truncation between amino acid position 79 and 137 resulting in and ORF of only 
87 amino acids in all three lineages (L1, L2 and L3). This deletion also caused a point 
mutation, changing leucine at position 137 of the parental H5N3/NS1/144 to valine at 
amino acid position 80 in the new, 87 amino acid long ORF. This virus is referred as 
H5N3/NS1/87, throughout this study. (Fig. 2). Interestingly, viruses in L2 and L3 had 
two additional point mutations in the RNA binding domain at position 40 where 
glutamine was replaced by arginine (Q40R) and at position 73 where a threonine was 
replaced by a methionine (T70M) (Fig. 11), and is referred throughout this study as 
H5N3/NS1/87P. 
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Fig.11. A. Truncated forms of NS1 ORF after serial passage of H5N3/NS1/144 in older 
age ECE. A. Agarose gel electrophoresis of RT-PCR products of the NS gene segment 
of H5N3/NS1/144 after 15 serial passages in older age ECE. PCR products for parental 
H5N3, NS1 mutant H5N3/NS1/144 and passage viruses from three different lineages 
(L1, L2 and L3) are shown. B. Schematic representation of the deletion and point 
mutations in each of the three passage lineages (L1, L2 and L3) of H5N3/NS1/144 in 
older age ECE. The NS gene of lineages 1 and 2 were incorporated into the wild-type 
H5N3 background using reverse genetics generating viruses H5N3/NS1/87and 
H5N3/NS1/87P, respectively.  
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To study the significance of the deletion and point mutations in virus replication 
and pathogenesis, these mutations were incorporated by reverse genetics into a parental 
virus background and phenotypic differences in vitro, in ovo and in vivo were examined. 
3.3.2 Viral Growth in ECE 
The growth properties of parental and NS1 mutant viruses was next assessed in 
7, 10 and 13-day-old ECE. Viability of embryos inoculated with H5N3, H5N3/NS1/144, 
H5N3/NS1/87 and H5N3/NS1/87P viruses was monitored every 8 hours to study the 
mortality pattern. Mortality pattern was based on percent dead embryos and MDT for 
each virus. As expected, all viruses tested caused 100% mortality and showed a very 
similar MDT (38-48 h) in 7- and 10-day-old ECE (Fig.12). On the other hand, when 
embryos were inoculated at 13-days of age, MDT ranged from 79-144 h, with the lowest 
MDT for H5N3 virus followed by H5N3/NS1/87P, H5N3/NS1/87and H5N3/NS1/144. It 
should be noted that not all the 13-day-old ECE died, and the MDT was calculated based 
on the number of dead embryos. Similar trend in mortality pattern was observed in three 
independent experiments. 
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Fig.12. Comparisons of mean death time (MDT) and embryo death percent (EDP) in 7, 
10 and 13-day old ECE. The bars indicate MDT and the lines indicate EDP. MDT was 
determined as described in materials and methods using 100 PFU/embryo. 
 
 
3.3.3 Growth Characteristics in Cell Culture 
Plaque phenotype has been shown to be an indicator of fitness and a correlate of 
virulence. Clear differences were noted in plaque size in all three lineages of 
H5N3/NS1/144 in older age ECE as shown in Fig. 13. While L1 formed smaller and 
indistinct plaques on MDCK, L2 and L3 formed plaques bigger than parental H5N3 and 
H5N3/NS1/144 viruses. In addition, H5N3/NS1/87 and H5N3/NS1/87P derived by 
reverse genetics presented plaque morphologies similar to passage lineage virus L1 and 
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L2 from which their respective NS gene segment was derived. This demonstrates that 
the plaque morphology on MDCK cells was determined by the truncation and point 
mutations in the NS1 gene segment.  
 
 
 
Fig.13. Plaque phenotypes of passage and reverse genetic generated viruses on MDCK 
cell monolayers 72 hours post infection. 
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Next, the growth properties of H5N3, H5N3/NS1/144, H5N3/NS1/87 and 
H5N3/NS1/87P viruses were assessed in A-CEC, as aging of chicken embryo cells has 
been shown to make chicken cells more interferon competent compared to non-aged 
cells (Sekellick & Marcus, 1985).  
To determine multi-step growth properties of the parental and NS1 mutant 
viruses, cells were inoculated at a low multiplicity of infection (0.001 PFU/cell) and 
supernatants from infected cells were collected at different time-points and titrated by 
plaque assay on DF1 cells. The growth kinetics of the NS1 mutant viruses in A-CEC 
was clearly different from parental H5N3 virus. As expected, H5N3/NS1/144 was the 
most compromised in growth, followed by H5N3/NS1/87 and H5N3/NS1/87P. At earlier 
time points (24-72 h), H5N3 grew to significantly higher titer compared to the NS1 
mutants. Titers for H5N3/NS1/144 reached a peak at 24h post-inoculation and then fell 
precipitously. Interestingly, an increase in viral titers was noticed for H5N3/NS1/87 and 
H5N3/NS1/87P at 96 hours post-inoculation and no significant differences were 
observed between H5N3, H5N3/NS1/87 and H5N3/NS1/87P at 120 h post inoculation 
(Fig.14. A). In contrast, all four viruses showed similar growth kinetics in infected DF1 
cells (Fig. 14. B). 
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Fig.14. Growth kinetics of recovered parental and NS1 mutant viruses in (A) DF1 and 
(B) A-CEC. Cells were infected at an MOI of 0.001 with the indicated viruses. Viral 
titers in infected cell culture supernatants were determined at the indicated times post-
inoculation by plaque assay on DF1 cells.  
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3.3.4 Interferon Induction by NS1 Mutant Viruses 
To examine whether the differences in the replication and virulence of parental 
H5N3 and NS1 mutant viruses were directly correlated with their respective abilities to 
inhibit the IFN-α/ß system, the production of IFN-ß in cells infected with these viruses 
was assessed. The relative levels of IFN-ß mRNA in A-CEC infected with 0.0001, 0.001 
and 0.01 MOI was quantified by real-time RT-PCR at 6 hours post infection. As shown 
in Fig. 15, H5N3/NS1/144 induced markedly higher levels of interferon mRNA than 
parental H5N3, H5N3/NS1/87P and H5N3/NS1/87 viruses. Within the NS1 mutant 
viruses expressing 87 amino acids the differences in levels of interferon induction were 
small, but were significantly higher for H5N3/NS1/87 compared to H5N3/NS1/87 at the 
two highest MOIs tested in this study. These results reflect the ability of H5N3/NS1/87P 
and H5N3/NS1/87 viruses to regain considerable virulence over the H5N3/NS1/144 
through their increased ability to inhibit interferon induction.  
 
 
 
 
 
 
 
 
 71 
 
Fig. 15. Quantification of IFN-ß mRNA synthesis by A-CEC infected with H5N3, 
H5N3/NS1/144, H5N3/NS1/87P and H5N3/NS1/87 at increasing MOI of infection (A: 
0.0001 MOI, B: 0.001 MOI, C: 0.01 MOI). Six-hours post infection, cells were 
collected, RNA extracted and IFN-β mRNA expression determined by real-time RT-
PCR. The results represent relative IFN-β mRNA levels normalized with levels of β-
actin mRNA. Levels of IFN-β induction increase with increasing MOI.  
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3.3.5 Replication and Virulence of NS1 Mutant Viruses in Chickens  
Groups of twenty-two 1-day-old chickens were inoculated via the 
intranasal/intra-choanal route with 104 PFU of H5N3, H5N3/NS1/144, H5N3/NS1/87P 
and H5N3/NS1/87 viruses or mock-infected with allantoic fluid without virus. One day 
after inoculation, five uninfected contact chickens were included in each of the infected 
groups of chickens to determine the ability of the viruses to transmit. Mild clinical signs, 
such as depression, dyspnea and gasping were noted in chickens infected with parental 
H5N3 virus and in few chickens infected with H5N3/NS1/87P but no mortality was 
recorded in any of the treatment groups. Four days post-inoculation, all chickens in each 
group, except the contact chickens, were euthanized and necropsy was performed. Gross 
lesions in the respiratory tract (trachea and lung) were recorded, and lungs were 
collected to determine virus titers. Typical lesions observed included, plum-colored 
consolidated areas on individual lobes of the lungs and in some chickens, mucoid 
tracheal plugs were also present. H5N3/NS1/87P and H5N3 infected groups had equal 
number of chickens (10/22) showing gross lesions, followed by H5N3/NS1/87 (7/22) 
and H5N3/NS1/144 (2/22). We were able to isolate virus from significantly greater 
numbers of chickens infected with H5N3 (17/22), followed by H5N3/NS1/87P (16/22) 
and H5N3/NS1/87 (14/22) compared to H5N3/NS1/144 (8/21). The average titers in 
lungs from chickens infected with H5N3 were 103.7 ELD50/g of tissue followed by 
H5N3/NS1/87P, H5N3/NS1/87 and H5N3/NS1/144 with 102.8 ELD50/g 101.7 ELD50/g 
101.3 ELD50/g, respectively (Table 3). Serconversion of contact chickens was observed 
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for one of the contact chickens infected with H5N3 virus, while none of the contact 
chickens in other groups seroconverted. 
 
 
Table 3. Gross lesions and virus isolation with mean titers from homogenized lung 
tissues four days post infection. 
 
* Virus was isolated 4 days post challenge from homogenized lung tissues 
** Number of chickens positive / number tested with average titers expressed as Log10 
ELD50 / g of homogenized lung tissue 
 
 
3.4 Discussion 
In recent years, economic losses associated with AI infections have resulted in 
the use of large-scale vaccination in certain countries. The objective of current vaccines 
is to increase resistance in chickens against field challenge virus, reduce mortality rates 
and more importantly, limit AIV shed into the environment (Iqbal, 2009). Reduced virus 
shedding not only results in decreased transmission of AIV among chickens, but also 
minimizes the risk of evolution of new AIV strains, which can infect humans (Iqbal, 
2009).  
 In recent years, there has been increased interest in using NS1 mutant viruses, in 
different animal species, as a potential live attenuated vaccines due to the anti-interferon 
Groups Gross 
Lesions 
Virus 
Isolation * 
H5N3 10/22 17/22 (3.7)** 
H5N3/NS1/144 2/22 8/21 (1.3) 
H5N3/NS1-87/80V 7/22 14/22 (1.7) 
H5N3/NS1-87/40R/73M/80V 10/22 16/22 (2.8) 
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function of NS1 and the ability of such vaccines to differentiate between vaccinated and 
infected animals (DIVA) (Quinlivan et al., 2005; Solorzano et al., 2005; Steel et al., 
2009; Wang et al., 2008). Efficacy of NS1 mutant viruses as live vaccine candidates 
studies should not only be evaluated based on attenuation and protection offered by the 
vaccine, but also by the stability of the mutation and its reversion to wild-type 
phenotype. This is very important especially for commercial poultry, where chicken are 
under a variety of production stresses, and NS1 mutant viruses, though attenuated, can 
still replicate and reach moderate titers (Quinlivan et al., 2005; Solorzano et al., 2005), 
giving the NS1 mutant vaccine virus the opportunity to mutate and regain virulence. In a 
recent study, we observed such a phenomenon with H5N3/NS1/144, a carboxy-terminal 
truncated NS1 mutant virus. Within five back-passages in chickens,the virus underwent 
mutations that resulted in deletion of the inserted stop codon and was able to express 
both the amino and carboxy ends of NS1 protein. The current study and other reports, 
underscore the importance of NS1 in viral pathogenicity (Cauthen et al., 2007; 
Quinlivan et al., 2005) and prove that NS1 mutant viruses are able to revert to virulence 
under severe immune pressure when propagated in interferon competent host systems.  
To further understand the strategies used by LPAI NS1 mutant viruses to 
compensate the anti-interferon function of NS1 in its host, we serially passaged 
H5N3/NS1/144 in increasing age ECE. Older age ECEs are considered to be more 
interferon competent (Morahan & Grossberg, 1970; Sekellick et al., 1990; Sekellick & 
Marcus, 1985) and are also considered a good system to assess pathogenicity of AIVs 
affecting chickens (Perdue et al., 1990). H5N3/NS1/144 was earlier characterized and 
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shown to be severely attenuated in vitro, in ovo and in vivo compared to the parental 
H5N3 virus. After fifteen serial passages of H5N3/NS1/144 in older age ECE, the NS1 
gene in all three lineages was further truncated (87 amino acids) with a point mutation 
occurring at the point of truncation (L80V). Viruses from two of three lineages also had 
point mutations at positions 40 (Q40R) and 73 (T73M), of the RNA binding domain.  
 These naturally selected mutant viruses showed differences in plaque phenotype 
when plated on MDCK cells. Large plaque size has been associated with better virus 
replication and virulence (Pappas et al., 2008).  Interestingly, the same truncation was 
also present as a part of mixed population after five rounds of back passage of 
H5N3/NS1/144 in 6-8 week old chickens. The significance of the further deletion in the 
144 amino acid long NS1 ORF is not known. However, it has been previously shown 
that shorter NS1 mutant proteins (<90 amino acids) are more stable, and are expressed at 
higher levels than longer mutant proteins (~140 amino acids) (Quinlivan et al., 2005; 
Solorzano et al., 2005). Recently, Lee et al., showed that serial passage in 14-day-old 
ECE of a virus with a natural truncation in NS1 also resulted in further truncations 
(Wang et al., 2008). However, in that report, the authors detected various sizes of the 
NS1 ORF while in this study, we consistently detected a deletion of 58 amino acids 
between amino acids 79 and 137. Although the cause of the differences observed is not 
known, they could be attributed to the different strains of LPAIV used in the two studies.  
 To study the role and importance of the naturally selected truncated forms of NS1 
along with the mutations in the RNA binding region, we used reverse genetics to 
construct two new NS1 mutant viruses: H5N3/NS1/87 and H5N3/NS1/87P which 
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differed from each other and parental virus only in the NS gene segment. Both, H5N3 
and H5N3/NS1/144 viruses showed stark contrast in their ability to replicate in A-CEC 
as expected and observed earlier. A-CECs were chosen as they have been reported to 
have higher interferon production potential compared to fresh chicken embryo cells 
(Sekellick et al., 1990). Replication of H5N3/NS1/87 and H5N3/NS1/87P in A-CECs 
was intermediate when compared to parental H5N3 and H5N3/NS1/144 viruses. 
Interestingly, at later time points (96 h post-inoculation) H5N3/NS1/87 and 
H5N3/NS1/87P showed a slight increase in titers, compared to a slight drop in viral titers 
for the parental H5N3 virus. To our knowledge, this change in growth kinetics pattern at 
later time points has never been reported. It is possible that the NS1 protein of 
H5N3/NS1/87 and H5N3/NS1/87P follow a different IFN inhibition pathway from the 
parent virus. A recent study demonstrated that in for some strains increased virus 
replication can out competed the antiviral response of the infected host (Grimm et al., 
2007). Therefore, further studies are required to understand the role of NS1 in the 
growth kinetics differences observed. On the other hand, growth kinetics in DF1 cells, 
which do not express interferon upon virus infection (Karpala et al., 2008), were the 
same for all four viruses examined, suggesting that the differences observed in A-CEC 
were due to differences in interferon induction. In addition, this observation also rules 
out the possibility of NS1 mutations affecting the replication ability of the virus.  
 Our study showed that levels of IFN-β induction increased with increasing MOI of 
infection.  In addition, the attenuation of virus replication in A-CEC correlated with 
levels of interferon mRNA induced by virus replication. These data suggest that shorter 
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forms of NS1 regained functionality allowing for better replication of virus in interferon 
competent systems as observed with swine and equine influenza viruses (Quinlivan et 
al., 2005; Solorzano et al., 2005). These data also explain, the natural selection of 
shorter forms of NS1 after serial passage of H5N3/NS1/144 under innate immune 
pressure. Of the two shorter NS1 mutants generated in this study, H5N3/NS1/87P, which 
contains two point mutations in the RNA binding domain, showed a very small but 
significantly lower level of IFN-β induction compared to H5N3/NS1/87, at the higher 
MOIs used in this study.  Although these differences could be attributed to the point 
mutations in the RNA binding domain, further biochemical studies are warranted to 
elucidate their role in the anti-IFN activity of H5N3/NS1/87P.  
 We also found that the pathogenicity of the NS1 mutant viruses was different in 
terms of their ability to cause embryo mortality in increasing age ECE. In 13-day-old 
ECE a sharp decrease in embryo mortality was observed for H5N3/NS1/144 compared 
to just a slight drop in embryo mortality for the other viruses tested. The MDT, which is 
considered a good measure of pathogenicity (Perdue et al., 1990), indicated that 
H5N3/NS1/87P was more pathogenic than H5N3/NS1/87 and slightly less pathogenic 
than parental H5N3 virus. A similar trend in pathogenicity of the NS1 mutant viruses 
was observed in terms of their replication and ability to cause lesions in chicken lungs 
(Table 1). Collectively, these data suggest that NS1 is a crucial virulence factor and 
under selective pressure larger truncations in the NS1 ORF are generated resulting in 
increased virulence compared to H5N3/NS1/144 virus. In addition, the point mutations 
detected in the RNA binding domain seem to have some added advantage in vivo; 
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however, additional functional studies are need to understand the role of these point 
mutations in virus replication.  
 In summary, in this study we have shown that the truncations detected in the NS1 
protein of passaged viruses play an important role in the virus reversion to virulence. In 
addition, these studies support that the use of NS1 mutant viruses as live vaccines should 
be taken with a word of caution, and vaccine candidates should undergo several back-
passages in chickens or older age ECE to ensure the stability of the NS1 gene, before 
they can be introduced as a live attenuated vaccines in the field. 
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CHAPTER IV 
 
SUMMARY 
 
NS1 is one of the avian influenza virus (AIV) proteins associated with virulence 
due to its anti-interferon activity (Garcia-Sastre et al., 1998; Krug et al., 2003). 
Interferon plays a crucial role in the innate antiviral defense mechanism of eukaryotic 
cells. There has been increased interest in using NS1 mutant viruses as “modified live 
vaccines” since deletions in NS1 result in attenuation in growth in immunocompetent 
hosts. Besides inhibiting the innate immune response, NS1 can also inhibit the adaptive 
immune response by inhibiting dendritic cell maturation and their capacity to induce T 
cell responses (Fernandez-Sesma et al., 2006). NS1 protein of influenza A viruses 
utilizes several different mechanisms for its anti-interferon activity and these 
mechanisms differ from one strain to another (Hayman et al., 2007; Hayman et al., 
2006). Most on the studies on the mechanisms of NS-1 anti-interferon activity have 
focused on human strains. However, the role and importance of NS1 in anti-interferon 
activity of LPAIV in chickens needs more investigation.  The rationale behind the 
present work is that by gaining knowledge into the role of NS1 in AIV pathogenesis in 
chickens, it will be possible to evaluate the use of NS1 mutant viruses as potential DIVA 
vaccines for poultry.  
The first part of this study focused on the development a NS1 mutant virus, 
which is attenuated in its growth in interferon competent systems, and the evaluation of 
its use as a live attenuated vaccine for chickens. The second part of this project 
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concentrated on the in vitro, in ovo and in vivo characterization of growth properties and 
pathogenesis of different NS1 mutant viruses to better understand the importance of NS1 
in virus-host interaction.  
The AIV under study is a low pathogenic H5N3 virus. Our laboratory has 
developed an eight-plasmid reverse genetics system to generate recombinant AIVs. 
Initially, the NS gene segment was manipulated to generate a NS1 mutant virus 
expressing only the first 144 amino acids. The H5N3/NS1/144 virus was significantly 
attenuated in growth in interferon competent systems in vitro, in-ovo and in-vivo.  In 
addition, attenuation of H5N3/NS1/144 correlated with lack of inhibition of interferon 
induction by the mutant virus, which was in accordance with published reports 
(Quinlivan et al., 2005; Solorzano et al., 2005). Once its attenuation was confirmed, 
H5N3/NS1/144 was evaluated as a live vaccine in chickens. H5N3/NS1/144 induced a 
good immune response, as measured by HI, and also protected chickens from lesions 
after challenge with parental H5N3. However, safety studies indicated that 
H5N3/NS1/144 could revert to virulence. Within 5 rounds of back passage of the virus 
in chickens, the inserted stop codon at position 144 of the NS1 ORF was deleted and the 
virus was able to express an almost complete NS1 protein.  As a consequence, the back-
passage viruses produced lesions, in the respiratory tract, similar to parental H5N3.  
However, based on the absence of antibodies against the carboxy end of NS1 it was 
possible to clearly differentiate H5N3/NS1-144 from parental H5N3 inoculated 
chickens. In an attempt to make a safer vaccine, we evaluated H5N3/NS1/144 as killed 
virus vaccine and compared its efficacy with that of parental H5N3 virus against a 
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homologous H5N3 challenge. As expected, both vaccine preparations induced similar 
antibody titers and reduced virus shedding considerably. H5N3/NS1/144 certainly 
showed potential to be used as a killed vaccine for its DIVA properties. 
As indicated earlier back passage of H5N3/NS1/144 in chickens caused the 
deletion of the stop codon we introduced in the NS1 gene of H5N3/NS1/144. 
Interestingly, one of the three back-passage lineages of H5N3/NS1/144 also had a virus 
population with an internal truncation in the NS1 coding region reducing the NS1 ORF 
to only 87 amino acids.  This further truncation was of interest because in swine and 
equine influenza viruses it was shown that shorter mutant NS1 proteins were more stable 
and were more functional than longer ones. To study the relevance and importance of the 
NS1 truncation observed during serial passage in chickens, we carried out serial 
passages of H5N3/NS1/144 in increasing age embroyonated chicken eggs (ECE). Older 
age ECE were chosen for two reasons: a) They are believed to be more interferon 
competent; b) The ability of AIV to grow in older-age ECE is an indicator of 
pathogenicity of the virus. After 15 rounds of serial passages in increasing age ECE the 
NS1 ORF was truncated. Interestingly, the truncation observed was similar to that 
observed in one of the chicken back-passage lineages. This suggests that there is some 
relevance for natural selection of shorter NS1 ORF.  In addition, two of the embryo 
passage lineage had two mutations at amino residues 40 (Q40R) and 73 (T73M) of the 
RNA binding domain. To understand the importance of the large truncation in NS1 ORF 
and the role of the two point mutations in the RNA binding domain, we incorporated 
these particular NS gene segments into the parental H5N3 background and recovered the 
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viruses. In vitro, in ovo and in vivo studies indicate that H5N3/NS1/87 and 
H5N3/NS1/87P  were more virulent and replicated better than H5N3/NS1/144; however, 
they were still partially attenuated compared to parental H5N3. Interestingly, 
H5N3/NS1/87P was more virulent than H5N3/NS1/87 in ovo and in vivo; however, in 
vitro replication studies in aged chicken embryo cells (A-CEC) did not show any 
significant difference between the two viruses. Further studies are required to identify 
the role of the RNA binding domain mutation in pathogenesis.  
Based on our results future lines of research should include the use of adjuvants 
such as TLR receptor ligands along with killed NS1 mutant vaccines, as this would 
mimic a live virus infection and boost an early immune response, which was absent in 
the oil adjuvanted vaccine used in this study.  It would also be interesting to compare the 
effect of the NS1 mutant viruses on host gene regulation especially with regards to the 
host immune response, this could provide information on the mechanism used by the 
NS1 mutant viruses with shorter NS1 proteins to counteract interferon pathway and 
increase virus replication compared to NS1 mutant with longer NS1 proteins. Also it 
would be of interest to study the effect of the point mutations at positions 40 and 73 in 
parental H5N3 virus and study its growth properties. 
 In summary: (1) H5N3/NS1/144, is not a safe live vaccine candidate; however, it 
can be safely used as a killed DIVA vaccine; (2) Any potential NS1 mutant live virus 
vaccine should undergo several serial passages in either older age ECE and/or in 
chickens to ensure its stability and safety; (3) Shorter NS1 proteins help the virus regain 
its virulence considerably; (4) Mutations at position 40 and 73 confer added advantage to 
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the virus expressing an 87 amino acids long NS1 protein in terms of virulence and 
replication in older age ECE and chickens.   
          Further studies on the role of NS1 protein domains and specific amino acids in anti-
interferon activity may lead to the development of improved live attenuated vaccines or 
other novel control strategies. 
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